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Abstract
The aim of this thesis is to understand the spread, persistence and prevention mechanisms
of infectious diseases by mathematical models. Microorganisms that rapidly evolve pose a
constant threat to public health. Proper understanding of the transmission machinery of these
existing and new pathogens may facilitate devising prevention tools. Prevention tools against
transmissions, including vaccines and drugs, are evolving at a similar pace. Efficient imple-
mentation of these new tools is a fundamental issue of public health. We primarily focus on
this issue and explore some theoretical frameworks.
Pre-exposure prophylaxis (PrEP) is considered one of the promising interventions against
HIV infection as experiments on various groups and sites have reported its significant effec-
tiveness. This study evaluates the effectiveness of Tenofovir gel, one of the widely used PrEPs
for women, through a mathematical model. Our model has excellent agreement with the exper-
imental data on the use of Tenofovir gel as a PrEP in South African women. Using our model,
we estimate both male-to-female and female-to-male transmission rates with and without Teno-
fovir gel protection. Through these estimates, we demonstrate that the use of Tenofovir gel as
a PrEP can significantly reduce the reproduction numbers, new infections, and HIV prevalence
in South Africa. Our results further show that the effectiveness of Tenofovir gel largely de-
pends on the level of adherence to the gel and the proportion of women under gel coverage.
Even though Tenofovir gel alone may not be able to eradicate the disease, as indicated by our
estimates of the reproduction numbers, together with other interventions, such as condom use,
it can serve as a strong weapon to fight against HIV epidemics.
Another promising drug-oriented intervention against HIV infection is antiretroviral treat-
ment (ART). We study some crucial aspects of this intervention on the HIV epidemic. ART
has the potential to reduce mortality and disease progression among HIV infected individuals.
It can reduce the viral load of the infected individual to an undetectable level and help prevent
new infections. Whether the treatment should begin early or be delayed is still under debate.
This study considers the impact of early versus delayed ART on the HIV epidemic and demon-
strates the optimum timing of ART initiation. Our results highlight the long-term consequences
of early treatment.
Finally, we investigate the consequences of vaccine implementation strategies for infec-
tious diseases. Vaccines are said to be the intervention with the most potential against many
infectious diseases. However, their success relies on proper and strategic management and
distribution. In an infectious disease, the degree of infection may vary widely among those
individuals. Reports show that individuals belonging to certain groups possess considerably
ii
higher risk for infection. Integrating this phenomenon into vaccination strategies, the host is
categorized into different groups to measure the outcome of the vaccination. A mathematical
model is proposed and analyzed to evaluate this measure. Our results suggest that vaccinating
a group with a certain priority may lead to effective elimination of the disease.
Keywords: Anitretroviral therapy (ART), HIV, Lyapunov functional, Pre-exposure pro-
phylaxis (PrEP), Vaccine.
iii
Co-Authorship Statement
This integrated-article thesis is based on three papers. Chapter 2 is based on the paper [1] for
which Dr. Xingfu Zou and Dr. Naveen K. Vaidya provide assistance in formulating the model
and in discussion. I was responsible for numerical calculations, analytical derivation of results,
and the manuscript preparation. Chapter 3 is based on yet to be published paper [2] in which
Dr. Xingfu Zou and Dr. Naveen K. Vaidya help in formulating the problem and I perform the
calculations. Chapter 4 is based on the paper [3] for which Dr. Xingfu Zou provides significant
assistance in various aspects.
References
[1] S.M.A. Rahman, N.K. Vaidya and X. Zou, Impact of Tenofovir gel as a PrEP on HIV
infection: A mathematical model, Journal of Theoretical Biology, 347, 151–159, 2014.
[2] S.M.A. Rahman, N.K. Vaidya and X. Zou, Impact of early antiretroviral treatment on
HIV epidemics: a mathematical model study, in preparation.
[3] S.M.A. Rahman and X. Zou, Modelling the impact of vaccination on infectious diseases
dynamics, Journal of Biological Dynamics, 9: sup1, 307–320, 2015.
iv
Acknowledgements
I would like to thank my supervisor Dr. Xingfu Zou for his helpful guidance and assistance
during the completion of my PhD studies. His insightful ideas, broad experience, and countless
useful discussions we had immensely helped me complete my dissertation. I am sincerely
grateful to Dr. Zou for his patience, support, understanding and valuable advice in both science
and application. I also like to thank Dr. Naveen Vaidya for his cordial help and technical
assistance in several projects. His valuable discussion and data interpretation helped me in
deeper understanding of applications of the models.
I would also like to thank Dr. Lindi Wahl, Dr. Geoff Wild and Dr. Pei Yu for their valuable
suggestions and critical discussions on various topics during my study period. Their lectures
and courses contributed a lot to the development of my foundation in research.
I like to thank Ms. Audrey Kager and Ms. Cinthia MacLean who were always helpful and
smiling. I also like to thank and remember my friends and colleagues in Applied Mathematics
and across the campus whose presence made this study a pleasant journey.
I wish to thank all my family, especially to my wife Monoroma for her love, patience and
sacrifice in the pursuit of my goals.
Finally, I thank my parents, my son Abid and daughter Rufaida for their love and affection.
v
Contents
Abstract ii
Co-Authorship Statement iv
Acknowledgements v
List of Figures ix
List of Abbreviations x
1 Introduction 1
1.1 Infectious diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Pathogens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.2 Modes of transmission . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.1.3 Host-defense and immune system . . . . . . . . . . . . . . . . . . . . 4
1.2 Disease prevention and control . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2.1 Vaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2.2 Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.3 Mathematical models in infectious diseases . . . . . . . . . . . . . . . . . . . 8
1.3.1 Epidemic models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.3.2 Stability analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Bibliography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2 Impact of Tenofovir gel as a PrEP on HIV infection 18
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.2.1 Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.2.2 Mathematical model . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.2.3 Parameter values and initial conditions . . . . . . . . . . . . . . . . . . 23
2.2.4 Data fitting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.3.1 Effect of gel on transmission rates . . . . . . . . . . . . . . . . . . . . 25
2.3.2 Reproduction numbers and effects of Tenofovir gel . . . . . . . . . . . 26
2.3.3 Effect of Tenofovir gel on new infections . . . . . . . . . . . . . . . . 27
vi
2.3.4 Effect of Tenofovir gel on HIV prevalence . . . . . . . . . . . . . . . 29
2.3.5 Adherence to Tenofovir gel application . . . . . . . . . . . . . . . . . 29
2.3.6 Sensitivity analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Bibliography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3 Impact of early antiretroviral treatment program on HIV epidemics 42
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.2 Mathematical Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.3 Model analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3.1 Well-posedness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.3.2 Basic reproduction number . . . . . . . . . . . . . . . . . . . . . . . . 48
3.3.3 Stability analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.3.4 Persistence of the disease . . . . . . . . . . . . . . . . . . . . . . . . . 50
3.4 Data fitting and parameter estimation . . . . . . . . . . . . . . . . . . . . . . . 52
3.4.1 Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.4.2 Parameter values and initial conditions . . . . . . . . . . . . . . . . . . 52
3.4.3 Data fitting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.5.1 Model fit to the data . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.5.2 Community immunity level . . . . . . . . . . . . . . . . . . . . . . . . 54
3.5.3 HIV transmission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.5.4 CD4+ T cell count loss and recovery . . . . . . . . . . . . . . . . . . . 55
3.5.5 Outcomes of treatment program . . . . . . . . . . . . . . . . . . . . . 56
Single group treatment program . . . . . . . . . . . . . . . . . . . . . 56
Multi-group treatment program . . . . . . . . . . . . . . . . . . . . . . 57
3.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Bibliography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
4 Modelling the impact of vaccination on infectious disease dynamics 71
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.2 Mathematical Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.3 Analysis of the model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.3.1 Well-posedness of the model . . . . . . . . . . . . . . . . . . . . . . . 74
4.3.2 Basic reproduction number . . . . . . . . . . . . . . . . . . . . . . . . 75
4.3.3 Global stability of E0 . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.3.4 Persistence of the disease . . . . . . . . . . . . . . . . . . . . . . . . . 78
4.3.5 Global stability of E∗ . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Bibliography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
vii
5 Conclusions and future directions 91
Curriculum Vitae 93
viii
List of Figures
1.1 Transfer diagram of infection. . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.1 Schematic diagram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.2 Data fitting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3 Comparison chart of new infection in one year with or without Tenofovir gel
intervention. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.4 Adult prevalence with and without Tenofovir gel interventions over five years. . 30
2.5 Reduction of female infections with respect to adherence and coverage. . . . . 31
2.6 Impact of adherence and coverage on ℜ0. . . . . . . . . . . . . . . . . . . . . 31
2.7 Impact of coverage on HIV prevalence. . . . . . . . . . . . . . . . . . . . . . . 32
3.1 Schematic diagram of infection. . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2 Data fitting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.3 Immunity level . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.4 New infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.5 Disease death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.6 Yearly death avoidance: single group target . . . . . . . . . . . . . . . . . . . 59
3.7 Yearly death avoidance: multi group target . . . . . . . . . . . . . . . . . . . . 60
3.8 Adult prevalence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.9 Effect of ART on ℜ0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.10 ART on ℜ0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.1 Saturating effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
ix
List of Abbreviations
AIDS Acquired immune deficiency syndrome
ART Antiretroviral therapy
DFE Disease free equilibrium
EE Endemic equilibrium
HIV Human immunodeficiency virus
IDUs Injection-drug users
MSM Men-sex-with-men
ODE Ordinary differential equation
PEP Post-exposure prophylaxis
PrEP Pre-exposure prophylaxis
STD Sexually transmitted disease
STI Sexually transmitted infection
TDF Tenofovir disoproxil fumarate
x
Chapter 1
Introduction
Infectious diseases pose a constant threat to human beings. Every individual on the earth can be
affected by a disease. The emergence and re-emergence of infectious diseases have become a
significant worldwide problem. Proper understanding of transmission mechanisms of diseases
caused by existing and new pathogens may facilitate devising prevention tools. Prevention
tools against transmissions, including vaccines and drugs, need to to be developed at a similar
pace to that of the microbes. Implementation and proper use of these sophisticated tools against
the microbes is another challenge. This thesis addresses this multi-faceted issue and explores
some theoretical frameworks. The current chapter intends to provide some basic information
about the infection mechanisms of microbes, their orientation, control mechanism and the role
of mathematical models in the epidemiology.
1.1 Infectious diseases
An infectious disease is caused by various microbes or pathogen. Most of them are usually
microorganisms. Few of them are visible by naked eyes. The most common pathogens are
different types of viruses and bacteria. Fungi and Protozoa are also known as pathogens and are
responsible for various diseases. Diseases caused by these pathogens are termed as ‘infectious’
as these pathogens can be easily transmitted from one infected person to another non-infected
person. The most common and well-known example of such diseases could be influenza or flu
that is caused by some kinds of viruses. HIV, mumps, measles, rubella, smallpox, malaria have
also caused millions of infections and deaths [11,38]. Many of these diseases are still prevalent
at local or global scales and threaten public health [53].
1
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1.1.1 Pathogens
As mentioned above, pathogens are solely responsible for causing an infectious disease. In this
sub-section we briefly review some common pathogens that cause diseases. We highlight the
life cycles and infection mechanisms of the pathogens that are useful and important informa-
tion in modelling their spread.
Bacteria: Bacteria, single-celled organisms, are well known microbes that cause various dis-
eases. However, most of the bacteria are harmless and some are even beneficial to human.
Bacteria are useful in producing cheese, yogurt, and chemicals and medicines. They also play
some critical role to synthesize food particles in our intestine to produce energy [50]. Insulin
that saves millions of diabetic patients is also produced from genetically modified bacteria.
Some bacteria, however, are harmful and life threatening. Gastritis, pneumonia, meningitis,
gonorrhea are some examples caused by various bacteria [42, 46, 50]. Most of the bacterial
diseases can be treated by antibiotics.
Viruses: Viruses are the most common and harmful microorganisms that cause severe dis-
eases to human and other species. Influenza or flu which probably no one can avoid, is caused
by viruses. Other examples of viral diseases include chickenpox, herpes, human papillomavirus
(HPV), mumps, measles, rubella, viral hepatitis, viral meningitis, and viral pneumonia [49].
Human immunodeficiency virus (HIV) is another deadly virus that spreads mainly through
sexual contacts and causes AIDS.
Viruses cannot live by themselves, and they need other living cells for their reproduction.
Unlike bacterial diseases, viral diseases cannot be treated by antibiotics. Since viruses use
host’s cells for reproduction, an antiviral drug could be highly toxic and life-threatening for
the host [40]. Thus, instead of killing the target cells, antiviral drugs are used to inhibit vi-
ral replication processes. Antiviral drugs act to limit the viral loads and helps keep the in-
fected individual healthy until host’s immune system controls the infection and eliminates the
pathogen [40, 42]. In terms of the well-known characterization of HIV replication process,
several antiretroviral drugs can be combined to hinder major steps of the viral replication such
as fusion, reverse transcriptase, protease, and integrase. The positive side of viral infections,
however, is that it develops immunity for the infected hosts which helps prevent them from a
successive infection.
Fungi: Fungi are microorganisms that widely vary in sizes from uni-cellular, such as yeast,
to multicellular, such as mushrooms and toadstools which can easily be seen with naked eyes.
Fungi play a critical role in decomposing dead materials which in turn provide nutrients to the
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land [40]. The life saving antibiotic penicillin is also produced from the fungus Penicillium
chrysogenum [23, 25]. Some fungi are harmful by causing infections to plants and animals.
Candidiasis, histoplasmosis, mucorycosis, ringworm are common examples of diseases caused
by fungi. Vaginal yeast and thrush are fungal diseases that can cause infection to the immuno-
compromised individuals relatively easily [40].
Protozoa: Protozoa are comparatively large single-celled organisms. Some protozoa are
useful. For example, in the sewage treatment systems, protozoa are used for decomposing
organic matters. Some others are human parasites that cause diseases, such as malaria, tox-
oplasmosis, cryptosporidiosis, trichomoniasis, leishmaniasis, amoebiasis, amoebic dysentery,
and acanthamoeba keratitis [35]. Protozoa can be spread through contaminated food, water or
through a vector or carrier like arthropod mosquito. The well-known protozoa species Plas-
modium vibax that causes malaria spread through female anopheles mosquitoes. When a fe-
male mosquito bites an infected person it receives the parasite plasmodium. The parasite grows
and reproduces inside the mosquito. When this mosquito bites another person the parasite can
be transmitted through its saliva to that person. Malaria is one of the leading death causing
diseases that is responsible for about 700,000 deaths each year worldwide [8].
There are some other pathogens that also cause infectious diseases, e.g parasitic helminths,
ectoparasites and prions [8, 40], but the above four are most related to the topics of this thesis.
1.1.2 Modes of transmission
Infectious diseases can spread in various ways and pathogens cause infections by different
modes of transmission. Some infections may take place through a direct contact while other
may be caused through indirect contacts. Transmission can also be made through carriers or
vectors. For examples, malaria, filariasis, west Nile, dengue, chikungunya, and many others
spread through mosquitoes. However, two modes of transmission are particularly interesting:
airborne diseases and sexually transmitted diseases, and they have been paid much attention.
Many diseases, e.g. influenza, SARS, are airborne and can be transmitted through air. The
airborne infection spreads from an infected person to an uninfected person through sneeze,
cough and even through laugh. The microbes that are discharged from an infected person
may remain on the dust particles or any other medium. An infection may take place when
these microbes are inhaled or reach mucus membrane of an uninfected person through body
contact [13]. Hand-shaking also could be a potential way for transmition of infections.
A significant number of diseases, on the other hand, are sexually transmitted diseases (STD)
and they are also transmitted through contaminated blood and semen, breastfeeding, or during
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childbirth. HIV is one of the most death causing STDs. Other STDs including herpes, syphilis,
gonorrhea, chlamydia and trichomoniasis also cause significant infection and mortality [52].
Among the infectious diseases, STDs are the most troublesome to public health, as many of
these diseases, such as AIDS and Herpes, cannot be cured and last for whole life. This poses
severe social and economic consequences. Due to longer infectious life, infected individuals
with STDs may contribute increased number of infections and hence remain a major problem
in prevention of diseases. Another critical aspect of STDs is that they may not produce any
symptoms to the infected person. As a consequence, infected individual may transmit infection
unknowingly. Drug resistance is also a major threat to fighting STDs worldwide [51]. All these
matters are reflected in HIV, which we witness about 37 million infections worldwide at the
moment [53]. Since the beginning of the epidemic, nearly 34 million people have died from
AIDS-related causes. HIV statistics shows that in 2014 alone about 1.2 million died of AIDS-
related illnesses and at the same year around 2.0 million people became infected with HIV [53].
HIV and AIDS are now almost everywhere in the world. However, Sub-Saharan African
countries are mostly affected. These countries have 25.8 million HIV-infected people and
contribute about 70% of the total global HIV infection [53].
1.1.3 Host-defense and immune system
The human body is equipped with a strong defense system to protect against pathogenic in-
fections. This defense system is designed to protect the host from very simple to sophisticated
attacks by the pathogens. Our skin acts as a first defense by drawing a barrier for any harmful
entities to get inside. Once this barrier is penetrated, some volunteers from the immune sys-
tem come forward to act as a secondary defense. A pathogen has to face several stages of the
immune defense before it can cause disease and harm to the host.
Our whole immune system is divided into two types innate immune system and adaptive
immune system. The innate immune system is comprised of various immune cells, neutrophils,
mast cells, natural killer cells, and monocytes, and can attack any suspected foreign intruders
with no prior knowledge about the intruders. The innate immune system has a natural ability
that can detect almost every invading microbes [1, 24]. This natural response is also referred
to as to non-specific defense mechanism as it takes action almost immediately as soon as the
pathogens enter into the body.
On the other hand, the adaptive immune system is antigen specific. It is also known as
cell mediated immune system and is comprised of B cell and T cell. This immune system
is much more complex than the innate immune system. It requires some information about
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the pathogens in order to attack them efficiently. Such information can be provided by some
components from the innate immune system or by somebody within the adaptive immune
system. The adaptive immune mechanism also keeps memory of the previous infections or
pathogens. This memory is used to prevent any successive infection at the first place before
any signal is received from the innate system [1,24]. Therefore, a pathogen cannot infect a host
successfully a second time unless it evolves significantly enough to evade the host’s adaptive
immune defense.
The combined efforts of innate and adaptive immune systems keep our body safe and
healthy. However, in some pathogenic infections, host-pathogen battle may last longer (e.g.
HIV infection) or immune defense may fail resulting in a tragic death of the host.
The infections that are cleared off by the innate immune system or by the drug supplement
can be repeated. That means the host may be infected again by the same pathogen. Usually,
bacterial infections fall into this category. On the other hand, viral infections cannot be cured
by drug supplement. The adaptive immune system itself can clear the viral infections and also
develop immunity. That is why most viral infections go away on their own in few days without
any medication. Since a viral infection boosts immunity successive infection by the same
virus seldom occur in the host. The host is now recovered permanently from that pathogenic
infection. However, some viral infections such as herpes, Hepatitis B and C, and HIV can
cause latent infection that lasts for a long time.
1.2 Disease prevention and control
One of the effective ways to control a disease is to reduce contacts. However, in the modern
life with increased interactions among individuals, this way is not easy to achieve. In addition
to maintaining social distance, alternate prevention measures need to be adopted. Vaccines and
drugs are the two widely used prevention tools that can potentially reduce transmissions and
control diseases.
1.2.1 Vaccines
A vaccine is used to boost immune system against some specific pathogen. The substance con-
tained in a vaccine has similar physical properties to those of a pathogen. Typically a vaccine
can be thought of a fake pathogen that has no ability to reproduce and to cause an infection.
It can be made of a weak or killed pathogen. As vaccines are similar to pathogenic microor-
ganism, they can stimulates the immune system of the host and builds up antibodies against
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the pathogens to recognize them as foreigners. Thus, whenever such a true microorganism is
encountered within a host, the immune system destroys it. This kind of phenomenon is known
as immunity. Thus, as long as a vaccine for a disease is available, it is an ideal means of pro-
tecting a healthy population from the disease. After Edward Jenner’s cowpox vaccine, known
as the first vaccine ever in history, numerous successful campaigns have been launched against
many infectious diseases [30]. In fact, vaccines have saved millions of lives. Before introduc-
ing the first measles vaccine in 1963, about 400,000 measles incidences used to be reported
in the United States every year [37]. Polio, rubella, mumps and other child diseases also used
to cause significant mortality and morbidity. With the implementation of the vaccines, these
diseases are no longer epidemic [37].
Vaccines also have had a successful history against the transmission of influenza, the most
common infectious disease around the world. Before the introduction of flu vaccines, control-
ling an influenza pandemic was an impossible task. It was estimated that about 20-50 million
people worldwide died in the outbreak of Spanish flu in 1918-19. A century later, the global
death toll for the 2009-10 pandemic was only around 300,000 [5]. It is the vaccine that has
reduced the casualty rate to such an extent. Influenza vaccination now becomes a routine
program. An individual is recommended to receive an updated flu-vaccine as a flu-season
approaches with newer strains of flu viruses.
Though vaccines are very effective against transmission, typically, there are limits on the
amounts, especially in developing countries. Thus, how to distribute the limited vaccines be-
comes crucial for optimal benefit. Social, economical and ethical issues could be major ob-
stacles in implementation of vaccines [36]. Certain groups of individuals may have higher
susceptibility to the infections than others. In influenza, for example, school-going children
can be infected more easily and can spread the disease more rapidly than other individu-
als [17, 26, 32, 33]. Thus to control infections by using vaccines, a proper distribution and
implementation strategy is very crucial. We address this issue in detail in Chapter 4.
1.2.2 Drugs
In addition to providing a cure, drugs can also play a significant role in reducing transmission.
Taken either as a Pre-Exposure Prophylaxis (PrEP) or as a Post-Exposure Prophylaxis (PEP)
they can prevent infection and reduce transmission. PrEP is prescribed for healthy individuals
who are expected to expose themselves to an infection while PEP is prescribed for the infected
individuals to stop or reduce transmission. In the case of malaria, for example, when individ-
uals plan travel to a malaria infected area, they are advised to take malaria medication [10].
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The medication could prevent travelers from malaria infection during their travel if bitten by
an infected mosquito.
For many diseases, like HIV, effective vaccines have not been developed yet. Typically,
vaccines take some time for development and production. During the interval when vaccines
are not available, drug-oriented interventions can be an alternative strategy for reducing the
infection burden. In HIV, remarkable progress has been reported on the use of Pre-exposure
Prophylaxis (PrEP) and Post-exposure Prophylaxis (PEP) [7,9,12,14]. Fairly extensive results
have been published indicating significant reduction of viral loads of HIV infected person
associated with antiretroviral therapy (ART). The reduction of viral load is linked to a less
transmission probability. Thus a drug oriented intervention could be a potential approach to
mitigate the current burden of HIV infection.
A large cohort study [27] on 889 heterosexual women with multiple partners has confirmed
the profound impact of Tenofovir gel, one of the PrEPs, in reducing HIV infections, and its
success has gained much attention around the world [3, 41]. Tenofovir gel is a coitally related
vaginal gel that can be used by women. Since HIV acquisition among women is significantly
high, this result is promising to subside the burden of HIV infections. Better understanding of
the effectiveness of Tenofovir gel at the population level can be helpful for proper implemen-
tation of this gel to gain optimal benefits in preventing HIV infections. We investigate in detail
the possible impact of Tenofovir gel on the HIV epidemic in Chapter 2.
Another successful episode of HIV prevention is the introduction of antiretroviral ther-
apy (ART). Successful trials and tests of ART have demonstrated its significant effectiveness
against HIV transmission and in suppress of viral loads [12]. Numerous results signifying the
potential of ART can be found in [12,14] and in the references therein. ART is expected to have
a major impact on the dynamics of HIV and perhaps ART can highly contribute to marking the
end of the HIV epidemic. However, trial results may not be translated to the population level
and they are limited by numerous factors [45]. Trial results provide a short term scenario and
are usually valid for ideal conditions or within a restricted environment. On the other hand,
HIV patients need ART for a long term (life time) as ART cannot cure HIV infection. In addi-
tion, HIV patients usually progress through different disease stages characterized by CD4+ T
cell counts. The disease progression is also attributed by viral loads of infected persons. Trans-
mission rates of infected individuals at different stages are different. The role of transmission
rates, detection of infections, proportion of treatment eligibility, period of treatment and many
other uncertainties could substantially affect elimination effort [45]. A mathematical model
can play an important role in discovering possible scenarios that help guide future directions.
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We explore some possible scenarios for HIV epidemic under ART intervention in Chapter 3.
1.3 Mathematical models in infectious diseases
Mathematical models have been used to study the dynamics of infectious diseases for more
than a century. In recent years, applications of mathematics in infectious disease have shown
remarkably growing trends. As a result, separate branches like mathematical epidemiology
have emerged. Rapid diagnostic test, available clinical data and electronic surveillance can
facilitate the applications of mathematical models to testing scientific hypotheses and to design
practical strategies [18, 22]. The emerging and reemerging diseases have stimulated the inter-
est in mathematical modelling. Models can provide estimates of underlying parameters of a
real world problem which are difficult or expensive to obtain through experiment or otherwise.
By estimating transmission rate, reproduction number and other variables and parameters (see
Chapter 3 and Chapter 4 for details), a model can predict whether the associated disease will
spread through the population or die out. It can also estimate the impact of a control measure
and provide useful guidelines to public health for further efforts required for disease elimina-
tion.
The earliest mathematical modelling can be traced back to the 18th century when Daniel
Bernoulli formulated a model for smallpox to estimate the effectiveness of variolation of healthy
population with smallpox [4,22]. However, mathematical models have been growing since the
middle of the 20th century after Kermack and McKendrick published their paper on epidemic
models in 1927 which contains threshold results that determines whether an epidemic outbreak
may occur or not [22,28]. Over the last two decades overwhelming increase in modelling prac-
tices has been exhibited in the biological sciences [2, 22, 43]. These models have addressed
many aspects of biological phenomena such as stages of infection, vertical transmission, dis-
ease vectors, macro-parasitic loads, age structure, social and sexual mixing groups, spatial
spread, chemotherapy, vaccination, quarantine, passive immunity, gradual loss of vaccine and
disease-acquired immunity [2,18,22]. Some models specifically focus on diseases like measles,
rubella, chickenpox, whooping cough, diphtheria, cancer, smallpox, malaria, filariasis, rabies,
gonorrhea, herpes, syphilis, and HIV/AIDS [2, 22, 33, 48].
1.3.1 Epidemic models
An epidemic model describes the transmission process and traces the number of infected pop-
ulation. Such a model can identify the number or proportion of population that left uninfected
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(b)
(a)
Figure 1.1: Two typical schematic diagrams for disease transmission. (a) SIRS infection, (b)
SEIR infection.
at the end of an epidemic. In epidemic models, concept of population compartments is widely
used [2, 15, 22, 39]. For mathematical convenience, these compartments are typically repre-
sented by letters such as S, E, I, and R denoting susceptible, exposed, infectious and recovered
populations, respectively. Individuals who are vulnerable to infection are known as susceptible
and belong to the S (susceptible) compartment. An individual who is already infected, but
does not show symptoms or is unable to infect others belongs to the E (exposed) compartment.
Once an infected individual starts infecting others, he/she is as an infectious and belongs to I
compartment. Finally, when an individual is cured from the infection he/she belongs to the R
(recovered) compartment. A recovered individual either remains there if he/she gets perma-
nent recovery or may become susceptible again and move back into S compartment. Various
models can be developed in terms of these compartments based on the nature of pathogens
and diseases such as SIS, SIR, SIRS and so on. If an infected individual becomes susceptible
again after cure, an SEIS or SIS type model would be appropriate for the disease dynamics.
Bacterial infections could be such an example of SIS models. On the other hand, if recovery
is permanent and the recovered individuals are no longer susceptible to that pathogen, as seen
in viral infection, then an SIR type model would be appropriate. In these modelling exercises,
population are assumed to be homogeneously mixed and individuals get infections or be cured
at constant rates. Some schematic diagrams are shown in Figure 1.1.
A simple example of an SIR compartment model can be given by the following system of
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ordinary differential equations (ODEs):
dS
dt = −βS I,
dI
dt = βS I − γI,
dR
dt = γI,
(1.1)
where β is the transmission rate and γ is the rate of recovery. Without considering the demog-
raphy of the host population, this simple model describes how sub-populations of susceptible,
infectious and recovered classes evolve. Model (1.1) has been modified by incorporating var-
ious factors to capture the main features of the problems that are concerned with, but such
modification naturally increase the complexity of the model and make the analysis challenging
and sometimes even impossible (see, e.g. [15, 19, 31, 39]). Therefore, balancing the rational-
ity and mathematical tractibility of a model always remains an important issue when using
mathematical modeling approach to study disease dynamics.
In model (1.1) the incidence term βS I is referred to as bilinear or mass action infection
which demonstrates that incidence increases with the numbers of susceptible and infectious.
Various other nonlinear incidence rates such as standard and saturated, with their mathematical
forms βS IS+I ,
βS Ia
b+αIa , βS
pIq, are also commonly used in the literature [19, 22, 29, 39]. For detailed
explanations of these incidences, readers are referred to [15, 22].
A key threshold outcome of an epidemic model is typically determined by the basic re-
production number, often denoted by ℜ0 which is defined as the total number of secondary
infections caused by a single infected individual during his/her entire infectious period in a
completely susceptible population [15,16]. Basic reproduction number is a fundamental deter-
minant of the dynamics of disease infection in the population level. An epidemic will outbreak
if and only if this number is larger than one. This threshold property provides important infor-
mation about the potential of disease spread and impact of control mechanisms [15,18,39]. To
eliminate epidemic by a control measure, one would be interested in reducingℜ0 to below one.
In the subsequent chapters of this thesis, one will see how to compute this threshold quantity
for complex models and some potential applications of ℜ0.
1.3.2 Stability analysis
Mathematical models are becoming more and more complicated when higher degree of non-
linearity is adopted to address real-world problems. Finding an explicit solution of these mod-
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els is almost impossible. Though numerical simulations can provide good approximating solu-
tions with fixed parameters, general solution may remain unknown. When general solution is
hard to achieve, stability analysis can be resorted to get a sense of solution’s behavior. In fact,
stability analysis can predict the long time behaviour of the model solutions very well.
In general, there are two types of stability analysis, local and global, widely used in the
literature. Local stability is concerned with behaviour of the model solution near an equilibrium
point, while global stability can describe solution behaviour in the whole domain. To define
the notion of stability more precisely, we provide few definitions and related theorems [20,21]
below which will be used in the subsequent chapters.
Consider an autonomous system defined by
x˙ = f (x), x ∈ U ⊂ ℜn (1.2)
where U is an open subset of ℜn and f : U → ℜn satisfies those standard conditions that
ensure existence and uniqueness of the solution to the initial value problem associated with
(1.2). Then xe is said to be an equilibrium of (1.2) if f (xe) = 0.
Definition: An equilibrium xe of (1.2) is said to be stable if for any given ǫ > 0 there is a
δ > 0, (usually depending on ǫ), such that
||x(t0) − xe|| < δ => ||x(t) − xe|| < ǫ ∀t > t0. (1.3)
If an equilibrium is not stable, then it is called an unstable equilibrium.
Definition: An equilibrium xe is said to be asymptotically stable if it is stable and for initial
values close to xe, the corresponding solution x(t) satisfies
lim
t→∞
x(t) = xe. (1.4)
An equilibrium xe is said to be globally asymptotically stable if it is stable and (1.4) holds for
any solutions of (1.2).
Definition: Let V : U ⊂ ℜn → ℜ be a continuous function. Then V is said to be positive
definite on U if
(i) V(0) = 0;
(ii) V(x) > 0 for all x ∈ U − {0}.
Theorem 1.3.1 Let xe = 0 be an equilibrium point of (1.2) and V be a positive definite function
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on a neighbourhood of xe.
(i) I f ˙V(x) ≤ 0, for all x ∈ U − {0} then 0 is stable.
(ii) I f ˙V(x) < 0, for all x ∈ U − {0} then 0 is asymptotically stable.
Definition: A function V : U ⊂ ℜn →ℜ is said to be Liapunov function for (1.2) if
(i) V is positive definite; and
(ii) ˙V(x) < 0, for all x ∈ U − {0}
Theorem 1.3.2 Assume that f (0) = 0 and V is a Lyapunov function in U for (1.2). Let E =
{x ∈ U : ˙V(x) = 0} and M is the largest invariant subset in E with respect to (1.2). Then every
bounded solution of (1.2) in U will approach M as t → ∞.
To determine local stability of an equilibrium, one can linearize the model at the equilibrium
point and check the signs of the real parts of all the eigenvalues of the corresponding Jacobian
matrix [15, 16]. Global stability can be determined by constructing a Lyapunov function [19,
29, 34]. For detailed procedures of these approaches, one can see [34, 39, 43, 44] and chapters
2, 3, and 4 of this thesis.
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Chapter 2
Impact of Tenofovir gel as a PrEP on HIV
infection: A mathematical model
2.1 Introduction
During the last three decades, HIV/AIDS—with fifty-five million infections and sixteen million
deaths [7]-has been one of the major threats to human beings. Despite remarkable progress on
HIV treatments, elimination of HIV/AIDS is still out of reach, and approximately two-and-
a-half million people get infected every year [5, 16]. Thus, the prevention of new infections
remains a great challenge.
A vaccine is presumably the ideal means of protecting the general (healthy) population [31].
However, in the case of HIV, such vaccines have not been developed. In 1994, the placebo-
controlled phase 3 trial of the rgp120 HIV vaccine showed only 6% effectiveness [11]. In 2007,
the two HIV vaccine trials (HVTN 502 and Merck V520-023) were suspended due to issues of
safety and efficacy [26]. The trial of the RV 144 HIV vaccine that induces humoral and cellular
immune responses reported only 31% efficacy [30]. While more vaccine trials are currently
underway [18], no successful HIV vaccine is available at present.
In the absence of a successful vaccine, drug-oriented interventions can be an alternate strat-
egy for reducing infection burden. Recently, remarkable progress has been reported on the use
of Pre-Exposure Prophylaxis (PrEP) [4,6,8,14,20,33]. PrEP is the administration of low-level
antiretrovirals, such as Tenofovir/TDF (Tenofovir disoproxil fumarate) and Truvada/TDF-FTC
(TDF co-formulated with emtricitabine) to the susceptible population, usually, before their
exposure to potential HIV sources. The oral TDF and TDF-FTC showed protection against
HIV-1 infection in heterosexual couples by 67% and 75%, respectively [1]. The studies [5,13]
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also found TDF-FTC to reduce infection by 62% among uninfected heterosexually-active men
and women, and 44% of infection among men and trans women who had sex with men. In
addition to the use of Tenofovir (alone or in combination with other drugs) as an oral intake,
Tenofovir has also been considered as a potential gel (a coitally-related vaginal gel to be used
by women) for preventing new infections [19]. A large cohort study [19] on 889 heterosexual
women with multiple partners has confirmed the profound impact of Tenofovir gel in reducing
HIV infections, and its success has gained much attention around the world [23, 24, 35].
Tenofovir gel is safe, without any renal toxicity, which is one of the most important safety
concerns of TDF [32]. The gel has the advantage of being less of a burden due to the method of
its application as it is used only within ±12 hours of sexual acts, unlike the other forms of TDF,
which require daily use [5, 13, 19]. According to Karim et al. [19], the gel is used by inserting
it into vagina for two times in a 24-hour period; one dose within 12 hours before sex and
another, as soon as possible, within 12 hours after sex [19]. In addition, the unique advantage
of this formulation is that women at risk can use it without their partners’ knowledge [35],
avoiding any potential objections from the partner. Better understanding of the effectiveness of
Tenofovir gel can be helpful for proper implementation of this gel to gain optimal benefits in
preventing HIV burden.
In this chapter, we develop a mathematical model to quantitatively understand the effective-
ness of Tenofovir gel for women in the control of HIV infection. Using our model and survey
data from South Africa, we estimate the male-to-female and female-to-male transmission rates
both with and without the use of Tenofovir gel. With these estimates we predict the role of
Tenofovir gel in reducing reproduction numbers and new infections. We also evaluate the role
of adherence and coverage in the success of Tenofovir gel when it is used as a PrEP against
HIV epidemic.
2.2 Methods
2.2.1 Data
We obtained our data from the CAPRISA (Centre for the AIDS Programme of Research in
South Africa) study [19]. In this study, 889 healthy women were selected and divided into two
subgroups: 445 women were prescribed with Tenofovir gel and 444 women with Placebo gel.
The number of new infections and the incidence rates were reported cumulatively during the
study period of two-and-a-half years. From the given incidence rate [19] in the unit of percent
women-year (i.e. the number of new infections, in one year, per one hundred susceptible
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women), we calculate the cumulative new infections as follows: the cumulative total number
of new infections is W0Tα, where W0 is the number of susceptible women participants, T is
the duration in the study (in year), and α is the incidence rate given in Karim et al. [19]. In
the group using Tenofovir gel, for example, after 6 months (12 year) the incidence rate was 6.0
percent women-year. With the initial recruited (445) women, the total number of infections is
calculated as 445 × 12 × 0.06. In the same way the total number of infections after 24 months
(2 years) is calculated as 445 × 2 × 0.056, where the cumulative incidence rate is 5.6 percent
women-year. The data obtained from our calculations are given in Table 2.1.
Table 2.1: Data obtained from our calculation based on CAPRISA study [19].
Months of follow-up : 6 12 18 24 30
Incidence rate : 6 5.2 5.3 5.6 5.6
(in Tenofovir gel arm)
Cumulative HIV infections : 13 23 35 50 62
(in Tenofovir gel arm)
Incidence rate : 11.2 10.5 10.2 10.2 9.1
(in Placebo gel arm)
Cumulative HIV infections : 25 47 68 83 101
(in Placebo gel arm)
Initial recruitment: Tenofovir gel arm = 445 women, Placebo gel arm = 444 women
2.2.2 Mathematical model
We develop an HIV dynamic model in which we divide the total population into two groups:
a general group and a study group. The general group consists of male and female subgroups.
Consistent with the experimental study [19], all the individuals in the study group are female,
and the study group is subdivided into the Tenofovir subgroup (individuals receiving Teno-
fovir gel) and the Placebo sub-group (individuals receiving Placebo gel). In our study, the
individuals in the general group receive neither Tenofovir nor Placebo gels. Each subgroup
is further divided into susceptible (S ) and infected (I) subgroups. We assume, for simplicity,
that the transmission occurs through heterosexual contact only. The susceptible women using
Tenofovir gel (S d) or Placebo gel (S c) become infected (Id or Ic, respectively) through effective
contact with infected males (Im) from the general population. Similarly, susceptible females
(S f ) of the general population group become infected (I f ) through contact with infected males,
Im. Here, the study group constitutes only 1% of the total population, and the contribution by
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the infected females in the study group (less than 0.2% of the whole population) to the new in-
fection is negligible compared to that by the infected females in the general group. Therefore,
we assume that the susceptible males get infected only by the infected females of the general
group, and ignore the terms (in model) for the new infection due to females in the study groups.
Note, however, that we also investigated our model by including the study population in the
equations of the general population, and found no change in the results. The definition and
symbols are summarized in Table 2.2-2.4. The schematic diagram showing the transmission in
this dynamics is given in Figure 2.1.
Table 2.2: Description of variables with initial values of model (2.2).
Parameter Description Initial Value Source
S m susceptible male in GP 33631 [19, 38]
Im infected male in GP 5248 [19, 38]
S f susceptible female in GP 31674 [19, 38]
I f infected female in GP 10446 [19, 38]
S d susceptible female under TG 445 [19]
Id infected female under TG 0 [19]
S c susceptible female under PG 444 [19]
Ic infected female under PG 0 [19]
GP=General population, TG=Tenofovir gel group, PG=Placebo gel group
Table 2.3: Fixed parameter values estimated from demographic data.
Parameter Description Value (per month) Source
Λm recruitment rate of S m 173 [34]
Λ f recruitment rate of S f 187 [34]
µ natural death rate 6.67 ×10−4 [9]
µl rate of leaving from the network due to age 2.38 ×10−3 estimated
ν disease induced death rate 6.1 ×10−3 [36]
The transmission rate from infected female to susceptible male is denoted by βm. Similarly,
the transmission rates from infected male to susceptible females in the general subgroup, the
Tenofovir subgroup, and the Placebo subgroup are denoted by β f , βd, and βc, respectively.
These transmission rates are given by
βi(t) = βi0ζi f (t), i = m, f , d, c,
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Table 2.4: Estimated parameter values.
Parameter Description Value (per month)
β f transmission rate from Im to S f 0.0785
βd0 per act transmission rate from Im to S d 0.0047
βc0 per act transmission rate from Im to S c 0.0085
βd transmission rate from Im to S d 0.0219†
βc transmission rate from Im to S c 0.0396†
βm = β f /2.3 transmission rate from I f to S m 0.0341
†Calculated by using (2.3)
Figure 2.1: Schematic diagram. The solid arrows between the compartments indicate transfer
of individuals while dashed-dotted arrows indicate cause of transfer of individuals.
where βi0 is the corresponding transmission rate per sexual act, and ζi f (t) is the average number
of sexual acts at time t. As seen in the data [19] the coital frequency for the study group
decreases approximately linearly. Thus, we fit a linear curve to this coital frequency data [19]
to obtain ζi f (t) = ζ f (t) = 7.25 − 0.17t, i = d, c, where t is in months. Thus, we have
βd = βd0ζ f (t),
βc = βc0ζ f (t).
(2.1)
Since the coital frequency data for the general population groups are not available, the trans-
mission rates βm and β f are assumed to be constant. We consider only the sexually active
population group (age 15–49 years) in this network, and individuals crossing this age group
leave our study at the rate of µl. We assume that there is no vertical transmission, and newly
matured populations (turning 15 years old) are recruited to the susceptible male and female
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subgroups of the general population at constant rates Λm and Λ f , respectively. The natural
death rate and disease death rate are denoted by µ and ν, respectively. Since no additional
subjects were enrolled in the study group and only one individual died from this group, we do
not include any birth/death term in the model for these sub-groups. With these assumptions,
the dynamics of infection can be modeled by the following ODE system:
˙S m = Λm −
βmI f S m
S f + I f
− (µ + µl)S m,
˙Im =
βmI f S m
S f + I f
− (µ + µl + ν)Im,
˙S f = Λ f −
β f ImS f
S m + Im
− (µ + µl)S f ,
˙I f =
β f ImS f
S m + Im
− (µ + µl + ν)I f ,
˙S d = − βdImS dS m + Im ,
˙Id =
βdImS d
S m + Im
,
˙S c = − βcImS cS m + Im ,
˙Ic =
βcImS c
S m + Im
,
(2.2)
where dots represent the derivatives with respect to time t.
2.2.3 Parameter values and initial conditions
For the CAPRISA study [19], the women were selected from rural (Vulindlela) and urban
(eThekwini) sites of South Africa. The total population in the rural site in 2007 was 90,000
[19]. Taking the similar proportion for the population in the network from the urban site, we
use the total population in our study to be 180,000 [19]. According to Statistics South Africa
(STATSSA) [34], 45% of the total population belongs to the age group 15–49 [34], among
which 48% are male and 52% are female. Among the total population, 12% belong to the
age group 10–14 [34], which helps us to estimate Λm = 173/month and Λ f = 187/month. As
mentioned above we assume that the recruitment only added to the susceptible subgroups of the
general group. Using the male HIV prevalence (13.5 % [38]) and the female HIV prevalence
(24.8% [19]) at the study site, we calculate the initial population in the general subgroups as
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Figure 2.2: Data fitting with β f , βd0, and βc0 as variable parameters. The solid green curve
shows the simulation of cumulative infection of Tenofovir gel user (Id) while dots are the
corresponding data. The red curve predicts the cumulative infection of Placebo gel user (Ic)
while squares are the corresponding data. The predictions fit the data very well.
S m(0) = 33631, Im(0) = 5248, S f (0) = 31674, and I f (0) = 10446. The average life time
of HIV infected individuals without any treatment is 13.5 years (8–19 years) [36], yielding
ν = 0.074 per year. The other (non-HIV) death rate of 15-49 age group in South Africa has
been recorded as 8 per thousand per one year [9], giving µ = 0.008 per year. Moreover,
individuals leave the study after 35 years (15–49 years), which yields µl = 1/35 per year.
The female-to-male transmission rate is usually smaller than the male-to-female transmission
rate [27, 28]. Nicolosi et al. [27] found that the ratio between male-to-female and female-to-
male transmission rates is 2.3; we therefore take βm = β f /2.3. The three transmission rates β f ,
βd0 and βc0, are estimated from fitting our model to the data.
2.2.4 Data fitting
The HIV infection data corresponding to the Tenofovir and the Placebo groups are given in
Table 2.1. We fix several parameters by estimating them from the demographic data (Table
2.3), and consider only β f , βd0, and βc0 as free parameters during the data fitting process. We
solve the ODE system (2.2) using ode45, an ODE solver in MATLAB. We further use the
MATLAB function ‘fmincon’ to estimate free parameters by minimizing the following error
function.
J = ΣNi=1
[
(Id(ti) − ˆId(ti))2 + (Ic(ti) − ˆIc(ti))2
]
,
Chapter 2. Impact of Tenofovir gel as a PrEP on HIV infection 25
where Id(ti) and Ic(ti) are the model solutions at time ti; ˆId(ti), ˆIc(ti) are data at time ti; and N is
the total number of data points for each group.
2.3 Results
2.3.1 Effect of gel on transmission rates
In model-fitting we have three free parameters β f , βd0, βc0. The estimated parameters are given
in Table 2.4, and the fitted curves are shown in Figure 2.2. The model fits the data very well.
To simplify the discussion, we approximate the average transmission rates βd and βc by
βd ≈ βd0D
∫ D
0
ζ f (t)dt,
βc ≈ βc0D
∫ D
0
ζ f (t)dt,
(2.3)
where D is the duration of the study period (here D = 30 months). The values of the estimated
parameters are β f = 0.0785, βd0 = 0.0047, and βc0 = 0.0085 (Table 2.4). By using (2.3), we
obtain βd = 0.0219 and βc = 0.0396.
The transmission rate from infected males to females under Tenofovir gel, βd, is 45%
smaller than that to females under Placebo gel, βc, i.e., the relative effectiveness of Teno-
fovir gel over Placebo gel is 45%. This result is consistent with the findings of the CAPRISA
study [19], in which 28% to 54% relative effectiveness of Tenofovir gel compared to Placebo
gel were found.
We estimate the transmission rate βd to be 72% smaller than β f , indicating that the use of
Tenofovir gel as a PrEP is 72% effective on reducing HIV transmission. It is worth noting that
βc is also 50% smaller than β f . This indicates that Placebo gel itself provides protection against
HIV infection. Though Placebo gel has no antiviral activity, a plausible explanation for this
protection is that it forms a physical barrier for HIV to reach the target cell. This is consistent
with the findings by Lai et al. [21] that the barrier at vaginal mucosa prevents the virus from
reaching the target cells (CD4+ T cells) lying beneath the epithelial cell layer. The reduction of
infection in the Placebo gel group may also be due to the fact that they received comprehensive
counseling to minimize the risk of infection [19]. The results suggest that the net magnitude of
the gel efficacy has to be interpreted carefully.
Chapter 2. Impact of Tenofovir gel as a PrEP on HIV infection 26
2.3.2 Reproduction numbers and effects of Tenofovir gel
We define the male reproduction number, ℜm0 , by the total number of new male infections
generated by an infected female individual in her entire life when she is introduced into an
entirely susceptible male population; and the female reproduction number, ℜ f0 , is defined by
the total number of new female infections generated by an infected male individual in his
entire life when he is introduced into an entirely susceptible female population. Furthermore,
we define the basic reproduction number, ℜ0, by the average number of secondary infections
of the same-sex generated by a typical infected individual in his/her entire life when he/she is
introduced into an entirely susceptible population. These numbers measuring the secondary
same-sex individuals are important to study the sex-focused interventions such as the female-
focused Tenofovir gel considered in this study.
From our model, the male and female reproduction numbers can be obtained as
ℜm0 =
βmS m(0)
(µ + ν + µl)S f (0) , ℜ
f
0 =
β f S f (0)
(µ + ν + µl)S m(0) .
Similarly, the basic reproduction number in the absence of interventions is given by
ℜ0 = ℜm0ℜ f0 =
βmβ f
(µ + ν + µl)2 . (2.4)
Using our estimates, we obtain ℜ0 to be 31.53, with ℜm0 = 3.93 and ℜ f0 = 8.02. This shows
that women are much more vulnerable to the infection, consistent with many experimental
findings [2, 15]. The basic reproduction numbers with and without interventions are summa-
rized in Table 2.5. Note that the female-to-male transmission rate is not affected by the use of
Tenofovir gel because only susceptible women, after having been tested for eligibility, use this
gel as an intervention. Thus the gel has no effect on the male reproduction number (ℜm0 ), and it
remains the same (ℜm0 = 3.93), whether the women use the gel or not. Importantly, by the use
of Tenofovir gel, ℜ f0 is reduced from 8.02 to 2.23, and the resulting ℜ0 is reduced from 31.53
to 8.82.
Several studies [12, 25], in which the sexes were not distinguished, estimate that the basic
reproduction number (ℜ0) of HIV infection in South Africa ranges from 4.5 to 7.0. In our
model, we consider the male and female populations separately. For such a model, similar
to vector-borne disease models, one faces a choice of either using ℜ0 = ℜm0ℜ f0 (as in (2.4)),
or ℜ0 =
√
ℜm0ℜ f0 to define the basic reproduction number. The former is more biologically
intuitive and tractable, while the latter is based on the next generation approach [37] and is
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mathematically more rigorous. For our model, if we adopt the latter, meaning that we account
for both male and female-borne “generations”, we would obtain ℜ0 =
√
ℜm0ℜ f0 by calculating
the spectral radius of the next generation matrix. Using the values of ℜm0 and ℜ f0 above, we
then obtain ℜ0 =
√
31.5 ≈ 5.61, which is consistent with previous studies [12, 25].
While the use of Tenofovir gel is significantly effective on reducing the basic reproduction
number,ℜ0 still remains quite large (> 1) even under the Tenofovir gel intervention. Therefore,
additional interventions (e.g. condom use) are needed to achieve the desired result ℜ0 < 1,
a sufficient condition for eradication of the disease from the community [10, 37]. Assuming
other additional interventions can reduce the transmission rates βm and β f by fraction q, i.e.
βm → (1 − q)βm and β f → (1 − q)β f , we obtain that
ℜ0 =
βmβ f (1 − q)2
(µ + ν + µl)2
with other interventions only, while
ℜ0 = βmβd(1 − q)
2
(µ + ν + µl)2
with a combination of other interventions and Tenofovir gel. This implies that to satisfy the
condition ℜ0 < 1, we require
q > 1 − (µ + ν + µl)√
βmβ f
= 0.82
with other interventions only, and
q > 1 − (µ + ν + µl)√
βmβd
= 0.66
if Tenofovir gel is added to other interventions. Thus, addition of Tenofovir gel to other in-
terventions significantly reduces the level of other interventions required for successful eradi-
cation of the disease (requirement of at least 82% effectiveness vs. requirement of only 66%
effectiveness).
2.3.3 Effect of Tenofovir gel on new infections
In this section, we consider the base-case, i.e. all susceptible women in the general population
group use the gel with 72% adherence, and present the sensitivity of the coverage and adher-
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Table 2.5: Effect of gel on HIV infection and reproduction numbers.
Transmission New infections New infections Basic Male repr. Female repr.
rates (βs) male (Tm) female (T f ) repr. number number number
(in 1 year) (in 1 year) (ℜ0) (ℜm0 ) (ℜ f0)
β f = 0.0785 3786 4847 31.53 3.93 8.02
βd = 0.0219 3311 1399 8.80 3.93 2.23
ence in a later section. We also assume that only susceptible women, after having been tested,
are eligible [5] to use Tenofovir gel. We note that there might be some women on continued
gel use from an unknown time of infection to the time of diagnosis. We ignore this time lag by
assuming a frequent testing scenario, in which the proportion of unidentified infected women
who are on continued gel is small.
Using the estimated transmission rates, we now calculate the total number of new infec-
tions. The total number of new infections of male and female, Tm(t) and T f (t), respectively,
can be obtained by integrating the infection terms of the model (2.2), and are given by
Tm(t) =
∫ t
0
βmI f (s)S m(s)
S f (s) + I f (s) ds,
T f (t) =
∫ t
0
β f Im(s)S f (s)
S m(s) + Im(s)ds.
With the estimated parameters the total number of new male and female infections, in one
year, are Tm(12) = 3, 786 and T f (12) = 4, 847, respectively. By using Tenofovir gel the total
male and female infections can be reduced to 3,311 and 1,399, respectively (Figure 2.3 and
Table 2.5). This result showing 71% reduction in the women’s infection due to Tenofovir gel
is remarkable, and highlights the potential of Tenofovir gel to be used as a PrEP. Compared to
Placebo gel [19], Tenofovir gel is 44% more effective on reducing new infections consistent
with the trial study [19]. As mentioned earlier, Tenofovir gel is used by susceptible females
only, and, as expected, male infection is reduced by 15% only.
We also calculate the probability of transmission per act from males to females [3] in the
general population, the Tenofovir population, and the Placebo population as 0.24%, 0.08%,
and 0.16%, respectively. These transmission probabilities are consistent with those found in
previous studies [3, 17, 29].
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Figure 2.3: Comparison chart of new infection in one year with or without Tenofovir gel inter-
vention.
2.3.4 Effect of Tenofovir gel on HIV prevalence
HIV prevalence is defined as the proportion of HIV infected individuals in the total popula-
tion. More precisely, male, female and overall prevalence are defined by no. of HIV positive mentotal no. of men ×
100%, no. of HIV positive womentotal no. of women × 100%, and no. of HIV positive individualstotal population × 100%, respectively. In the ab-
sence of interventions, both male and female prevalences increase over time as shown by the
five year HIV dynamics (Figure 2.4). However, these HIV prevalence patterns can be altered
by the use of Tenofovir gel as a PrEP. The overall HIV prevalence as well as the male and
female prevalences can drastically be reduced by Tenofovir gel. In a five-year period, the use
of Tenofovir gel as a PrEP reduces the overall, the male, and the female prevalences by 44%,
15% and 61%, respectively.
2.3.5 Adherence to Tenofovir gel application
As seen above, the use of Tenofovir gel significantly reduces the transmission rate. If r repre-
sents the reduction of transmission rate due to the gel, then
(1 − r)β f = βd. (2.5)
Using our estimates of β f and βd, we obtain r = 0.721 (∼ 72%). In this section, we further
highlight that r primarily depends on two factors, the effectiveness (ǫ) of Tenofovir gel and
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Figure 2.4: HIV prevalence (see Section 2.3.4 for definitions) of male, female and overall
population with and without Tenofovir gel interventions over five years. The top three (solid
line) curves represent prevalence with no gel while the bottom three (dashed line) curves rep-
resent prevalence with gel. The blue colour represents overall prevalence while red and green
represent male and female prevalence respectively.
the adherence (a) to its application. The Tenofovir gel is prescribed as two doses within a
24-hour period of a sexual act; one dose of the gel within 12 hours before sex and another as
soon as possible, within 12 hours after sex [19]. Since the average number of sexual acts for
the study group is 5 per month (i.e. ≈1/week) [19], we may reasonably assume that the use
of gel in the 24 hour-period of one sexual act does not affect the next sexual act. Assuming
that the reduction rate r increases linearly with the adherence level, for a simple case we take
ǫa = r = 0.721. Using the adherence level of 72.2%, reported in the trial study [19], we find
that the gel efficacy is 99.86%, and use these values for the base-case computation.
We now evaluate the sensitivity of adherence on the reproduction numbers, new infections,
and the prevalence. Note that in our simple model of ǫa = r, the sensitivity of the adherence
level is equivalent to the sensitivity of the efficacy. When the adherence level is changed from
72.2% to 60% and to 80%, female infections are reduced by 59% and 79%, respectively, in one
year under 100% coverage (Figure 2.5). Similarly, for 60% and 80% adherence levels, the basic
reproduction number is changed to 12.61 and 6.31, respectively, and the female reproduction
number is changed to 3.21 and 1.61, respectively. In these adherence levels (60% and 80%),
the overall HIV prevalence reaches 44.37% and 33.46%, respectively, at the end of 5 years.
Note that this effect depends upon the gel coverage of susceptible female population. Thus,
we further evaluate how changes in the coverage affect this outcome. Let us assume that a
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Figure 2.5: Reduction of female infections (in one year) with respect to adherence and cov-
erage. The reduction rate increases with adherence and coverage. The adherence level 72.2%
was observed in the study group [19]. Four different colour bars denote percentage of coverage.
Figure 2.6: Impact of adherence and coverage on ℜ0. (a) Full image; (b) Highlighted area
where ℜ0 passes through 1.
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Figure 2.7: Impact of coverage on prevalence. The top three (solid line) curves represent preva-
lence with 60% gel coverage while the bottom three (dashed line) curves represent prevalence
with 80% gel coverage. The blue colour represents overall prevalence while red and green
represent male and female prevalence, respectively.
fraction c of the susceptible women are under the gel coverage, i.e. these women are infected
at the rate of βd, while the remaining fraction, 1-c, of the susceptible women are infected at
the rate of β f . As mentioned earlier, only susceptible women use Tenofovir gel; so it does not
affect the infectivity of infected women to transmit the virus to susceptible men. Therefore, the
gel does not affect the female-to-male transmission rate, βm, or the male reproduction number,
ℜm0 . However, the gel affects ℜ f0 , which is given by
ℜ f0c =
(1 − c)β f S f (0)
(µ + ν + µl)S m(0) +
cβdS f (0)
(µ + ν + µl)S m(0) ,
for the coverage c. By using (2.5), the above formula becomes
ℜ f0c =
(1 − c)β f S f (0)
(µ + ν + µl)S m(0) +
c(1 − ǫa)β f S f (0)
(µ + ν + µl)S m(0) ,
and the corresponding basic reproduction number, from (2.4), is given by
ℜ0c = ℜm0ℜ f0c.
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As seen in Figure 2.6, ℜ0c decreases as the level of adherence and/or the coverage increases,
and it becomes less than one if the product of the adherence and coverage levels is greater than
0.97 (Figure 2.6). The coverage also significantly affects the new infections (Figure 2.5) and
the disease prevalence (Figure 2.7). For example, at 80% adherence level, if the coverage is
increased from 70% to 90%, the reduction of yearly new infections increases from 56% to 71%
of that of the case without the tenofovir gel (Figure 2.5). Similarly, at 100% adherence level,
when the coverage is increased from 60% to 80%, the male prevalence, the female prevalence,
and the overall prevalence are reduced by 6%, 15%, and 11%, respectively (Figure 2.7).
2.3.6 Sensitivity analysis
To determine the robustness of our parameter estimates, we performed a sensitivity analysis by
varying the fixed parameters by ±20%. We found that the estimations were insensitive to the
change in most of the parameters. The most sensitive parameters are the initial values of the
male and female prevalence. The sensitivity of the estimated parameters subject to the fixed
parameters is provided in Table 2.6. When we vary the male and female initial prevalence
randomly between 10% to 30%, the estimated transmission rate βd0 varies between 0.0032 and
0.0060. Similarly, β f varies between 0.0652 and 0.0869, and βc0 varies between 0.0073 and
0.0110. The sensitivity analysis shows that our estimation is robust.
Table 2.6: Sensitivity of the estimated parameters on the fixed parameters.
Fixed parameters Base-value Changes Changes in Changes in Changes in
(%) β f (%) βd0(%) βc0(%)
Λm 173m−1 ±20 0.01 0.37 0.47
Λ f 187m−1 ±20 0.01 0.37 0.47
µ 6.67 × 10−4m−1 ±20 ±0.03 0.37 0.47
µl 2.38 × 10−3m−1 ±20 -0.08 0.38 0.48
ν 6.1 × 10−3m−1 ±20 ±2.48 0.45 0.54
initial 13.5% ±20 ±13.97 ±22.39 ± 22.27
male-prevalence
initial 24.8% ±20 ±7.65 ±2.26 ± 2.35
female-prevalence
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2.4 Discussion
Tenofovir gel is one of the candidates with the highest potential for pre-exposure prophylaxis
to provide protection to uninfected women who are at high risk of HIV infection. This is not a
vaccine, but using it regularly or according to prescribed guidelines it may provide vaccine-like
protection. The experimental data has revealed the significant effects of Tenofovir gel on pro-
tecting vulnerable women from HIV infection [19]. Thus Tenofovir gel has been thought to be
an important potential PrEP in the absence of effective HIV vaccines as in the current situation.
It is not yet well understood how much impact Tenofovir gel can have on population-level HIV
dynamics when it is distributed as a PrEP to susceptible women in the community. Here, we
developed a mathematical model to better understand the possible implications of Tenofovir
gel as a PrEP against an HIV epidemic. Our model is consistent with the experimental data on
the use of Tenofovir gel as a PrEP in South Africa (Figure 2.2).
This study provides the HIV transmission rates from male-to-female and from female-to-
male with and without the use of Tenofovir gel. We found that Tenofovir gel can reduce the
male-to-female transmission rate by 72%. As a result, yearly women infections can be reduced
by almost 80% (Figure 2.5) when Tenofovir gel is used as a PrEP. Given the nature of the gel
application, i.e. only susceptible women use it, it is expected that the gel does not have direct
impact on the female-to-male transmission rate. However, the male population also receives
a benefit of 15% annual infection reduction due to indirect female protection. These annual
reductions of male and female infections also reflect on the long-term prevalence (Figure 2.4).
By implementing the gel as a PrEP over the five-year period, the male and female prevalence
can be reduced by 15% and 61%, respectively, with 44% reduction in the overall prevalence. As
demonstrated by our results, these remarkable effects of Tenofovir gel on reducing infection
rates, new infections, and prevalence further highlight the potential of Tenofovir gel for its
broader use as a PrEP.
We defined and calculated the male (female) reproduction number, ℜm0 (ℜ f0), as well as
the basic reproduction number (ℜ0). Without intervention, our estimates provide ℜ0 = 31.53
for the Vulindlela and eThekwini regions of South Africa. This high value of ℜ0 reflects the
devastating impact of the HIV/AIDS epidemic in South Africa. Our estimation shows that
the female reproduction number (ℜ f0) is twice that of the male reproduction number (ℜm0 ),
indicating that women are particularly vulnerable to HIV infection as mentioned previously
[2, 15]. With the use of Tenofovir gel as a PrEP by susceptible women, both ℜ0 and ℜ f0
can be brought down significantly to 8.80 and 2.23, respectively. However, despite the use of
Tenofovir gel, ℜ0 still remains greater than 1, implying that the use of Tenofovir gel alone will
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not be able to eliminate the disease. A partial explanation for the lack of strength of Tenofovir
gel to eradicate disease could be that Tenofovir gel does not reduce the male transmission rate
(or male reproduction number), and the infection of women is governed by the infected male
population. Thus our results suggest that a combination program incorporating Tenofovir gel
as a PrEP into other additional interventions, such as condom protection, may result in the
successful eradication of HIV/AIDS.
Our results support the hypothesis that adherence and coverage are key for the success of
Tenofovir gel as a PrEP. The individual protection depends on the adherence level while over-
all impact depends on the coverage of susceptible women by Tenofovir gel. Both adherence
and coverage have a positive effect on the reduction of infections, reproduction numbers, and
prevalence (Figures 2.5, 2.6, 2.7). These observations suggest that the adherence and coverage
must be taken into account while evaluating the outcomes of Tenofovir gel as a PrEP. Moreover,
HIV prevention programs with Tenofovir gel as a PrEP need to be designed aiming at a higher
level of adherence and coverage. For example, to increase the adherence level, an alternate
form of Tenofovir gel, such as an intravaginal ring (IRV) [22], can be suggested. Similarly, an
optimal coverage can be achieved by identifying women at high risk and bringing them under
gel coverage.
One of the interesting findings of our study is that Placebo gel also shows some effective-
ness against HIV infection, as opposed to the general expectation that Placebo gel has negligi-
ble effect. To understand this in detail, we also considered the model with β f = βc assuming
that Placebo gel has no effect. Interestingly, we found that the model with β f = βc provides
significantly worse fit (p = 0.0025, F-test) to the data compared to our original model. This
surprising effect could be due to the fact that though Placebo gel does not contain any anti-viral
agent, it may form a physical barrier against HIV reaching the target cell [21]. It may also be
due to the fact that the study group under Placebo gel received comprehensive counseling to
minimize the risk of infection. The results suggest that the net effectiveness of Tenofovir gel
has to be interpreted carefully.
While this study offers some valuable insights into the implication of Tenofovir gel as a
PrEP on HIV dynamics, we identify several limitations of our study. Our estimates are based
on limited data sets from South Africa. We assumed that the adherence of gel increases the
protection linearly, which may not be the case for each individual. The drug concentration
and its efficacy might also play a role in determining the overall effects on transmission. Our
model further assumes that only susceptible women use Tenofovir gel [5]. However, there
might be some infected women on continued gel from the time of infection to the time of
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diagnosis. To the best of our knowledge, there is no clear evidence about the effects of gel
on the transmission from women to men. If these unknowingly-infected women continue gel
use, which may provide additional protection not accounted for in our study, then the benefits
of Tenofovir gel can be expected to be more than those found in this study. In this case,
we have underestimated the benefit from Tenofovir gel. While these infected women on the
continued gel use can be ignored in some regions with frequent testing facilities as in our
computation, the model needs to be improved to include this group in the regions with poor
resources. Finally, we acknowledge that the women in the experimental study [19] benefited
from supplementary care, including education, counseling, and motivation; our estimates of
the benefits from Tenofovir gel might have been affected by these. Further studies with more
data sets may help achieve a deeper understanding of the actual benefit of Tenofovir gel as a
PrEP.
In summary, Tenofovir gel as a PrEP for women can be an effective tool to fight against
HIV infection. In the absence of a successful vaccine, Tenofovir gel can be used as a PrEP
to provide significant direct protection to women, and indirectly to men, from HIV infection.
In combination with other interventions, Tenofovir gel as a PrEP has the potential to eradicate
HIV/AIDS, the most devastating current human epidemic. A strategic and prudent use of this
gel is required to obtain the optimal impact.
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Chapter 3
Impact of early antiretroviral treatment
on HIV epidemics: A mathematical model
study
3.1 Introduction
Prevention of HIV transmission has been one of the prime concerns and challenges in the past
three decades. Repeated failure of vaccine development aggravates this challenge [22, 34, 38].
In the absence of vaccines, the use of antiretroviral agents such as pre-exposure prophylaxis
(PrEP) and post-exposure prophylaxis (PEP) has shown promising results [9,11,13,16]. In par-
ticular, trials on early antiretroviral therapy (ART) as prevention have demonstrated significant
effectiveness in reducing HIV transmission [13, 16, 21].
A study with 1763 serodiscordant couples from nine countries found 89% reduction of HIV
transmission with early initiation of ART [13]. Similarly, a community based cross-sectional
study in South Africa estimated up to 71.8% reduction of annual risk of HIV transmission with
early ART [5]. This is mainly because of the significantly lower viral load in successfully
treated individuals [16].
In addition, ART can help recover the CD4+ T cell population in infected individuals. It
is well established that the CD4+ T cell count is a crucial marker that plays an important role
in immunity and treatment decisions during HIV infection [28, 46]. CD4+ T cells, the main
target for HIV infection, are rapidly depleted during the disease progression towards AIDS.
CD4+ T cell count measurements have been central to understanding HIV disease progression,
making important clinical decisions, and monitoring the response to antiretroviral therapy [20,
42
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28, 32, 46]. The measurement of CD4+ T cell counts also has an important role in decisions
for screening and prophylaxis for major opportunistic infections, including malaria, severe
bacterial infections, P. jiroveci pneumonia, and toxoplasmosis [42]. Thus, it is important for
public health to know the proportion or number of HIV infected individuals that belong to
certain CD4+ T cell count thresholds under a treatment program.
Several studies and modelling efforts outlined the possible impact of initiation timing of
ART and found a reduction of HIV incidence associated with early initiation of ART [8, 23,
31,33,41]. A comprehensive test-and-treat model among MSM in New York City showed that
the cumulative number of new infections can be reduced by 69.1% over a 20-year period [41].
Another study showed a reduction of disease progression and serious non-AIDS events when
ART was initiated before the CD4+ T cell count was reached 350 cells compared with delaying
until the CD4+ T cell count had dropped to less than 250 [46]. A dynamical model developed
by the World Health Organzation (WHO) predicted that annual HIV testing and immediate
treatment could reduce HIV incidence and mortality in South Africa to less than 1 case per
thousand people per year in five years and HIV prevalence to less than 1% in fifty years [23].
However, none of these studies considered the fact that ART improves the immunity level of
the infected individuals (i.e. increases their CD4+ T cell counts) [4]. Improved immunity
tends to reduce the death of infected individuals and slows the disease progression. Moreover,
improved immunity collectively benefits community health which is important for controlling
other opportunistic diseases. The actual contribution of treated individuals to the total number
of new infections, the immunity level of the community, and HIV prevalence is not well un-
derstood. Thus, the quantification of these measurements is important for better formulating
treatment strategies.
Moreover, the timing of ART initiation is important for increased levels of immunity and
decreased disease mortality and morbidity. Depending on the time of ART initiation, an HIV
patient may even have a normal life expetancy. A longitudinal cohort study found increased
AIDS-related mortality and morbidity associated with delay in initiation of ART [6]. In the
French cohort [4, 20], ART patients who maintained CD4+ T cell count > 500 had mortality
similar to those in the general population. Since ART reduces the transmission rate, but pro-
longs the life span of the HIV infected individual, the initiation time of ART is critical to the
outcomes of ART programs. In this study, we develop a model to explore the consequences
of various ART programs and their initiation timing on the population-level HIV transmission
dynamics.
The remainder of this chapter is organized as follows: in Section 3.2 we develop a mathe-
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matical model. Basic properties of the model and stability analysis are presented in Section 3.3.
In Section 3.4, we estimate parameters and perform data fitting. In Section 3.5, the results from
various treatment programs are shown. Finally, we summarize our findings with discussions in
Section 3.6.
3.2 Mathematical Model
In HIV infection, an individual’s disease condition is associated primarily with their CD4+
T cell count. In fact, HIV primarily weakens an infected individual’s immune system by de-
stroying their CD4+ T cells. Therefore, CD4+ T cell count is a crucial marker to measure
the strength of the immune system in HIV infected individuals [6, 28]. Moreover, a decision
as to whether the treatment should begin or not is usually made based on a patient’s CD4+
T cell level. Here we develop a model based on an individual’s CD4+ T cell count level.
In ART programs, HIV infected individuals are generally divided into three groups or stages
based on their CD4 T+ cell counts (below 350, 350-500 and above 500) and receive mild to
strong recommendation for initiating ART [2, 46]. Based on these guidelines, we divide the
total HIV infected population into three stages according to their corresponding CD4+ T cell
levels. Stage I consists of the individuals with CD4+ T cell counts more than 500, stage II
with CD4+ T cell count between 350 and 500, and stage III with CD4+ T cell count less than
350. Once infected, an individual generally progresses through these stages if they remain un-
treated. The individual usually regains their CD4+ T cell count through treatment [29]. The
amount of CD4+ T cell count recovery depends on the level of CD4+ T cell count at the time
the person begins treatment. In addition to the regain of CD4+ T cell count, the treatment can
also suppress the viral load down to an undetectable level. Thus, an infected individual be-
comes significantly less infectious under treatment [40]. In our model, the treatment can have
two consequences: increase in CD4+ T cell count in treated individuals and decrease in HIV
transmission by treated individuals.
We consider a homogeneous sexually active (age 15-49 years) population and divide them
into seven groups: a susceptible group, S, three infected groups (categorised based on CD4+ T
cell count) without treatment, I1, I2, I3 and three infected groups (categorised based on CD4+ T
cell count) with treatment, T1,T2,T3. The transmission dynamics are as follows: a susceptible
individual moves to the compartment I1 when he/she comes in successful contact with an indi-
vidual from any of the infected compartments. The individuals of I1 either get treatment and
move to T1 at the rate of τ1 or they move to I2 compartment (due to their CD4+ T cell count
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Figure 3.1: Schematic diagram of infection.
decline) at the rate of δ1. Similarly, individuals move from compartment I2 to T2 at the rate of
τ2 (treatment) or to I3 at the rate of δ2 (CD4+ T cell decline). The individuals of compartment
I3 get treatment and move to T3 at the rate of τ3. Treated individuals gain CD4+ T cell count
and move from T3 to T2 and from T2 to T1 at rates ρ2 and ρ1, respectively.
The infectivity of individuals at different stages are different [15]. The rate of transmission
by HIV infected individuals without treatment is high during acute infection (few months),
decreases to a low level that continues for a long period (usually 6-7 years), and then increases
slightly during the last 2-3 years [27]. Therefore, we take different transmission rates, β1, β2,
and β3 for I1, I2, and I3 compartments, respectively. Since the viral load of individuals in all
treated compartments usually remains low with a low transmission probability [13, 40], we
do not distinguish infectivity of different compartments of treated groups, and take the same
transmission rate β for all T1,T2, and T3. The definition and symbols of the model variables
are summarized in Table 3.1-3.2. The flow of the population in these transmission dynamics is
shown in Figure 3.1.
Following the assumptions discussed above, the infection dynamics can be modeled by the
following system of ODEs :
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Table 3.1: Description of variables of model (3.1).
Variable Description
S number of susceptibles
I1 number of infected individuals with CD4+ T cell count > 500
I2 number of infected individuals with CD4+ T cell count 350-500
I3 number of infected individuals with CD4+ T cell count < 350
T1 number of treated individuals with CD4+ T cell count > 500
T2 number of treated individuals with CD4+ T cell count 350-500
T3 number of treated individuals with CD4+ T cell count < 350
N total number of individuals
˙S = Λ − (λ + µ0)S
˙I1 = λS − (τ1 + δ1 + µ2)I1
˙I2 = δ1I1 − (τ2 + δ2 + µ4)I2
˙I3 = δ2I2 − (τ3 + µ6)I3
˙T1 = τ1I1 + ρ1T2 − µ1T1
˙T2 = τ2I2 + ρ2T3 − (ρ1 + µ3)T2
˙T3 = τ3I3 − (ρ2 + µ5)T3
(3.1)
where the force of infection, λ, is given by
λ =
β1I1 + β2I2 + β3I3 + β(T1 + T2 + T3)
N
e−a(I1+I2+I3+T1+T2+T3),
and
N = S + I1 + I2 + I3 + T1 + T2 + T3.
The exponential term in λ represents ‘behavioural changes’ due to media or social awareness
[35]. When the number of infected individuals is small, this term has negligible effect and the
effect increases as the number of infected individual increases.
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Table 3.2: Description of parameters of (3.1).
Parameter Description
Λ recruitment rate
λ force of infection
β1 transmission rate for I1
β2 transmission rate for I2
β3 transmission rate for I3
β transmission rate for treated groups
τ1 rate of treatment for I1
τ2 rate of treatment for I2
τ3 rate of treatment for I3
δi rate of transfer due to CD4+ T cell decline (i=1,2)
ρi rate of transfer due to CD4+ T cell increase (i=1,2)
µi rate of death (i=0,1,...,6)
a rate associated with reduction of incidence due to behavioral changes
3.3 Model analysis
3.3.1 Well-posedness
The model (3.1) has seven coupled equations. Following [37] it can be shown that S (t) ≥ 0.
Similarly, we can show that all the other state variables are also non-negative as long as the
initial values are non-negative.
By adding all the equations of (3.1), the total population N satisfies
˙N ≤ Λ − µN,
where
µ = min{µ0, µ1, µ2, µ3, µ4, µ5, µ6}.
By comparison, it implies that limt→∞ sup N ≤ Λ/µ. Therefore, the total population is bounded.
This suggests that the biologically feasible region of the model is given by
Γ = {(S , I1, I2, I3,T1,T2,T3) : S , I1, I2, I3,T1,T2,T3 ≥ 0, N ≤ Λ/µ} .
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3.3.2 Basic reproduction number
The basic reproduction number, denoted by ℜ0, of a model is a threshold value that determines
whether the disease persists or dies out. It is defined as the total number of secondary infections
caused by a typical infected individual in a completely susceptible population [18]. Using the
next generation matrix approach [44], the new infection and the transfer matrices of our model
are given by
F =

β1 β2 β3 β β β
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0

, V =

α1 0 0 0 0 0
−δ1 α2 0 0 0 0
0 −δ2 α3 0 0 0
−τ1 0 0 α4 −ρ1 0
0 −τ2 0 0 α5 −ρ2
0 0 −τ3 0 0 α6

,
where
α1 = τ1 + δ1 + µ2, α2 = τ2 + δ2 + µ4, α3 = τ3 + µ6, α4 = µ1, α5 = ρ1 + µ3, α6 = ρ2 + µ5.
It follows that
ℜ0 = ρ
(
FV−1
)
=
β1
α1
+
β2δ1
α2α1
+
β3δ2δ1
α3α2α1
+
β
α5
(
δ1
α1
τ2
α2
+
δ1
α1
δ2
α2
τ3
α3
ρ2
α6
)
+
β
α6
(
δ1
α1
δ2
α2
τ3
α3
)
+
β
α1
(
τ1
α1
+
δ1
α1
τ2
α2
ρ1
α5
+
δ1
α1
δ2
α2
τ3
α3
ρ2
α6
ρ1
α5
)
.
(3.2)
3.3.3 Stability analysis
The model (3.1) has a unique disease free equilibrium (DFE), E0 = (Λ/µ0, 0, 0, 0, 0, 0, 0), and
possibly an endemic equilibrium (EE) E∗. The existence of endemic equilibria is given in the
following sub-section. The stability analysis of these equilibria can reveal whether the disease
can survive or not. According to [44], we have the local stability result of E0, given in the
following theorem:
Theorem 3.3.1 If ℜ0 < 1, the DFE, E0, is locally asymptotic stable, and if ℜ0 > 1, E0 is
unstable.
We can further prove that E0 is globally asymptotically stable:
Theorem 3.3.2 If ℜ0 < 1, the DFE, E0, is globally asymptotically stable.
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Proof. Let us consider the auxiliary function
L = c1I1 + c2I2 + c3I3 + c4T1 + c5T2 + c6T3, (3.3)
where ci, i = 1...6 are positive constants to be determined. Taking the derivative of L, with
respect to t, along the trajectories of (3.1), we have
˙L =c1 ˙I1 + c2 ˙I2 + c3 ˙I3 + c4 ˙T1 + c5 ˙T2 + c6 ˙T3
=c1(λS − α1I1) + c2(δ1I1 − α2I2) + c3(δ2I2 − α3I3) + c4(τ1I1 + ρ1T2 − α4T1)
+ c5(τ2I2 + ρ2T3 − α5T2) + c6(τ3I3 − α6T3)
≤c1β1I1 + β2I2 + β3I3 + β(T1 + T2 + T3)N S − c1α1I1 + c2δ1I1 − c2δ2I2
+ c3δ2I2 − c3α3I3 + c4τ1I1 + c4ρ1T2 − c4α4T1
+ c5τ2I2 + c5ρ2T3 − c5α5T2 + c6τ3I3 − c6α6T3
≤c1(β1I1 + β2I2 + β3I3 + β(T1 + T2 + T3)) + (c2δ1 − c1α1 + c4τ1)I1
+ (c3δ2 − c2α2 + c5τ2)I2 + (−c3α3 + c6τ3)I3 − c4α4T1
+ (−c5α5 + c4ρ1)T2 + (c5ρ2 − c6α6)T3
=(ℜ0 − 1)[β1I1 + β2I2 + β3I3 + β(T1 + T2 + T3)],
(3.4)
where
c1 =
β1
α1
+
β2δ1
α2α1
+
β3δ2δ1
α3α2α1
+
β
α4
(
τ1
α1
+
δ1
α1
τ2
α2
ρ1
α5
+
δ1
α1
δ2
α2
τ3
α3
ρ2
α6
ρ1
α5
)
+
β
α5
(
δ1
α1
τ2
α2
+
δ1
α1
δ2
α2
τ3
α3
ρ2
α6
)
+
β
α6
(
δ1
α1
δ2
α2
τ3
α3
)
,
c2 =
β2
α2
+
β3δ2
α3α2
+
βτ3δ2
α2α3α6
+
βρ1(τ2α3α6 + ρ2τ3δ2)
α2α3α4α5α6
+
β(τ2α3α6 + ρ2τ3δ2)
α2α3α5α6
,
c3 =
β3
α3
+
βτ3
α3α6
+
βρ1ρ2τ3
α3α4α5α6
+
βρ2τ3
α3α5α6
, c4 =
β
α4
, c5 =
β
α5
+
βρ1
α4α5
,
c6 =
β
α6
+
βρ1ρ2
α4α5α6
+
βρ2
α5α6
.
Therefore, ˙L ≤ 0 when ℜ0 < 1 with the equality holding only when state variables regarding
infection are zero. By Theorem 3.1 (page no. 143 in [25]), all positive solutions approach
M, the largest invariant subset of the set { dLdt = 0}. Since dLdt is zero only at disease free state,
M = {E0} is a singleton set. Thus, the equilibrium E0 is globally attractive. By virtue of the
Theorem 3.3.1, E0 is globally asymptotically stable.
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3.3.4 Persistence of the disease
In the previous section, we proved that if ℜ0 < 1 then the disease dies out regardless of the
initial size of the outbreak. On the other hand, when ℜ0 > 1 the DFE becomes unstable. In
this sub-section, we show that the infectious populations I1, I2, I3,T1, T2 and T3 will remain
persistent in this case.
Theorem 3.3.3 Assume that R0 > 1. Then the disease is uniformly persistent in the sense that
there exists an η > 0 such that for every positive solution of (3.1), there holds
lim inf
t→∞
Ii(t) > η, lim inf
t→∞
Ti(t) > η, i = 1, 2, 3.
Moreover, there exists an endemic equilibrium E∗ in this case.
Proof. We apply a theorem in [43] to prove the uniform persistence. To this end, let
U = (S , I1, I2, I3,T1,T2,T3), ¯U = (I1, I2, I3,T1,T2,T3),
X =
{
U ∈ R7+|Ui ≥ 0, i = 1...7,where Ui is the i’th component of U
}
,
X0 =
{
U ∈ X|Ui > 0, i = 2...7
}
,
Y = X/X0 =
{
U ∈ X|Ui = 0, for some i = 2...7
}
.
Now we show that the system (3.1) is uniformly persistent with respect to (X0,Y). Since
Y contains a single equilibrium E0, it is sufficient to show that W s(E0) ∩ X0 = φ, where
W s(E0) denotes the stable manifold of E0. Suppose this is not true. Then there is a solution
(S , I1, I2, I3,T1,T2,T3) ∈ X0 of (3.1) such that
lim
t→∞
(S (t), I1(t), I2(t), I3(t),T1(t),T2(t),T3(t)) → (Λ/µ, 0, 0, 0, 0, 0, 0).
Then for any ξ > 0, we have
Λ
µ
− ξ ≤ S ≤ Λ
µ
+ ξ,
0 ≤ Ui ≤ ξ, i = 2...7
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for large t. It follows from the system (3.1) that

˙I1
˙I2
˙I3
˙T1
˙T2
˙T3

=

λS
0
0
0
0
0

+

−α1 0 0 0 0 0
δ1 −α2 0 0 0 0
0 δ2 −α3 0 0 0
τ1 0 0 −α4 ρ1 0
0 τ2 0 0 −α5 ρ2
0 0 τ3 0 0 −α6


I1
I2
I3
T1
T2
T3

,
≥

β1 ˜S (ξ) − α1 β2 ˜S (ξ) β3 ˜S (ξ) β ˜S (ξ) β ˜S (ξ) β ˜S (ξ)
δ1 −α2 0 0 0 0
0 δ2 −α3 0 0 0
τ1 0 0 −α4 ρ1 0
0 τ2 0 0 −α5 ρ2
0 0 τ3 0 0 −α6


I1
I2
I3
T1
T2
T3

,
≡ ˜J(ξ) ¯U,
where,
˜S (ξ) = Λ/µ0 − ξ
Λ/µ0 + 7ξ
,
and
˜J(0) =

β1 − α1 β2 β3 β β β
δ1 −α2 0 0 0 0
0 δ2 −α3 0 0 0
τ1 0 0 −α4 ρ1 0
0 τ2 0 0 −α5 ρ2
0 0 τ3 0 0 −α6

. (3.5)
Note that ˜J(0) is equal to (F − V), has at least one eigenvalue with positive real part when
ℜ0 > 1 [44]. Since ξ > 0 is arbitrary, one can make ξ small enough so that s( ˜J(ξ)) is positive,
where s(A) is the largest real part of the eigenvalues of A. Then there exist solutions of the
linear system
˙
¯U = ˜J(ξ) ¯U ,
that grow exponentially near ¯U = 0. By comparison, the solutions ¯U become unbounded as
t → ∞. This is a contradiction to the fact that the solutions of the system (3.1) are ultimately
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Table 3.3: HIV prevalence data from South Africa [48].
Year : 1990 1991 1992 1993 194 1995 1996 1997 1998 1999 2000 2001
Prev.: 0.3 0.6 1.1 2.0 3.3 5.0 7.0 9.2 11.3 13.2 14.9 16.2
Year : 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Prev. : 17.1 17.8 18.3 18.5 18.7 18.8 18.9 18.9 18.9 18.8 18.9
bounded. Therefore, W s(E0) ∩ X0 = φ. Following Theorem 4.6 [43], it can be concluded that
system (3.1) is uniformly persistent with respect to (X0,Y).
Furthermore, system (3.1) is dissipative, therefore, by Theorems 3.3 in [24], it implies that
system (3.1) has an endemic equilibrium E∗ (i.e. all components are positive). The proof of
the theorem is complete.
Due to the presence of nonlinear incidence with an exponential term in the model (3.1),
the stability analysis of E∗ becomes a challenging task. We leave this analysis and move to
applications of the model with data fitting. In the following sections, we fit the model (3.1) to
HIV prevalence data and obtain some results of ART programs.
3.4 Data fitting and parameter estimation
3.4.1 Data
We used the World Bank data for HIV infection in South Africa [48]. The yearly adult HIV
prevalence data from 1990 to 2012 were considered. The ‘adult prevalence’ is defined as the
percentage of adult infected individuals among the 15-49 years old population. The data are
given in Table 3.3.
3.4.2 Parameter values and initial conditions
HIV mortality is primarily attributed to CD4+ T cell counts and disease stage; the mortality
is higher in patients with low CD4+ T cell counts. Mortality is also highly affected by treat-
ment. An individual with successful treatment can have almost a normal life [4]. Following the
previous studies [6, 8, 30], we estimated the mortality rates of the individuals in different com-
partments as µ0 = 0.0288, µ2 = 0.0888, µ4 = 0.1368, µ6 = 0.3108, µ1 = 0.0408, µ3 = 0.0528
and µ5 = 0.1752.
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HIV infected individuals, if they remain untreated, are highly infectious during the first
few months (stage I) [15]. Then the infectivity declines and remains low during the asymptotic
period for about 6-7 years (stage II), followed by an increase to a higher level during stage III.
To represent these different infectivities for I1, I2, and I3, we set β1 = m1β2, β3 = m2β2, and
estimate the constants m1,m2. On the other hand, the trated individuals have little contribution
in transmission. The reduction of trasnmission due to treatment could reach as high as 96%
[13]. Folowing this result, we considered β = 0.04 × β2. Since no treatment was available for
the individuals with higher CD4+ T cell counts, we take τ1 = 0, and τ2 = 0 for data fitting.
The population [19, 48] corresponding to the year 1990 is taken as the initial value as the
data begins at the year 1990. According to Day et al. [17] and Dorrington et al. [19], 37.08
million people lived in South Africa in 1990, among which 45% were adult (15-49 years).
Using HIV prevalence data [48] and CD4+ T cell count distribution among HIV positive in-
dividuals [5] we calculated the initial population for our model to be S (0) = 17.94 million,
I1(0) = 0.0163 million, I2(0) = 0.009 million, and I3(0) = 0.011 million. Since there were no
treatments available for HIV infected individuals in South Africa in 1990, the initial popula-
tions in treatment compartments are taken to be zero.
3.4.3 Data fitting
We fit the model (3.1) to the data (Table 3.3) to estimate nine parameters δ1, δ2, ρ1, ρ2, τ3,
m1, m2, a, and β2. The parameters are estimated using MATLAB built-in functions ‘ode45’
and ‘fmincon’ to minimize the following error function
E =
i=23∑
i=1
(
I1(ti) + I2(ti) + I3(ti) + T1(ti) + T2(ti) + T3(ti)
N(ti) × 100 − P(ti)
)2
,
where I1(ti), I2(ti), I3(ti),T1(ti),T2(ti),T3(ti), N(ti) are numerically computed model solutions at
time ti and P(ti) is the HIV prevalence data at time ti.
3.5 Results
3.5.1 Model fit to the data
We obtained some of the model parameters from the primary literature [4, 6, 8, 29, 30], and
estimated the remaining nine parameters by fitting the model to the World Bank data (Table
3.3) [48]. The model solution using the best parameter estimates along with the data are shown
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Figure 3.2: Data fitting result. The solid green curve shows the yearly adult prevalence of HIV
infections predicted by the model and squares are the data (Table 3.3).
in Figure 3.2. The model fits the data very well. The set of parameter values that generates the
best fit is given in Table 3.4.
3.5.2 Community immunity level
The immunity of individual is divided into three levels: high, intermediate, and low. The
immunity level is high if CD4+ T cells count of the individual is above 500, intermediate if
the count falls between 350 and 500, and low if the count is below 350. According to our
model setting, individuals belonging to stage I (I1 & T1) have the high immunity level whereas
individuals at stage II and stage III have intermediate and low immunity levels, respectively.
The fraction of individuals in the community at each immunity level can be used as health
indicators of the community and are important for public health management to control other
opportunistic diseases. We define these fractions as community levels of immunity which we
investigate under various HIV treatment programs. Our model predicts that in the presence of
CD4+ T cell recovery, the high, intermediate and low immunity levels can reach to 90%, 8%,
and 2%, respectively in 5 years. However, when recovery rates are considered to be absent
(ρ1 = ρ2 = 0), those immunity levels become 51%, 32%, and 17%, respectively (Figure 3.3).
These estimates thus show the effect of recovery of CD4+ T cells on immunity levels.
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Figure 3.3: Community immunity level in 5 years under universal treatment with antiretroviral
therapy. Solid curves show the immunity levels in absence of recovery of CD4+ T cells and
dashed curves show the immunity levels in the presence of CD4+ T cells recovery.
3.5.3 HIV transmission
Our estimates show that the value of m1 and m2 are 12.57 and 4.54 indicating β1 is about 13
times higher and β3 is about 5 times higher than β2. These estimates are consistent with the
experimental results which found m1 between 7 and 26 and m2 between 2 and 6 [27, 40, 45].
These results show that HIV-infected individuals in stages I and III have more contribution than
stage II to the transmission of HIV, thus implying that individuals in these groups (I & III) can
be potential targets for treatment as prevention of HIV transmission. With these transmission
rates, our model predicts that the total new infections generated in 5 years by the individuals
in the stages I, II, III are 1.89 million, 0.11 million, and 0.47 million, respectively, without
treatment, while they reduce to 0.58 million, 0.029 million, and 0.11 million, respectively,
with treatment.
3.5.4 CD4+ T cell count loss and recovery
The disease progression rates estimated by our model are δ1 = 0.33 and δ2 = 0.34. That is, an
HIV infected individual, if untreated, takes about 3 years, on average, to progress from stage I
to stage II, and also 3 years from stage II to stage III. These progression rates are in agreement
with the experimental results [26, 28, 32]. Our estimates of CD4+ T cell count recovery rates,
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Table 3.4: Values of the estimated parameters .
Parameters Estimated value (per year∗)
β2 0.082
m1 12.57
m2 4.54
ρ1 0.57
ρ2 0.82
δ1 0.33
δ2 0.34
τ3 0.11
a 2.4744e-7 (∗per number)
β1 = m1β2, β3 = m2β2
ρ1 = 0.57, ρ2 = 0.82, show that with treatment HIV patients can recover CD4+ T cell count
to the level of above 350 within 1 year on average and to the level of above 500 within the
next 2 years on average. This finding of CD4+ T cell recovery rates is in agreement with the
experimental results [29] in which the median of CD4+ T cell count is found to be increased
from 180 to 350 in about 15 months and from 350 to 500 in about 21 months after initiation of
ART.
3.5.5 Outcomes of treatment program
In this section, we evaluate the outcomes of various treatment programs on HIV epidemic.
We particularly focus on the single group and the multiple group treatment programs. For the
purpose of demonstration, we presented our simulation for the treatment rate from 0 to 1 per
year. However, our simulation can be easily extended beyond to higher treatment rates. For
longer term, our qualitative results do not change.
Single group treatment program
We estimated the total new infections generated during the five year period from 2015 to 2020
as a function of treatment rates τ1, τ2, τ3 (Figure 3.4), implemented one at a time (single group).
As expected, te results show that treatment can reduce infections significantly. However, it is
important to note that treatment at stage I can reduce the total number of new infections by 50%
and 45% more than those at stage II and stage III, respectively. More importantly, treatment at
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stage I alone is more effective at reducing new infections than the treatments at stages II and
III combined (Figure 3.4 a,b).
The effect of treatment on disease death is also remarkable. However, in contrast to the
effect seen in preventing new infections, treatments at the different stages are not significantly
different in preventing disease death during this 5 year period (Figure 3.5 a). Almost 30% of
disease death can be reduced by implementing any of the single group treatment programs (i.e.
τ1 or τ2 or τ3 = 1). This result is important as it predicts that the early treatment strategy might
not be significantly beneficial in preventing deaths.
The yearly death avoidance (YDA) (number of individuals’ lives saved per year) increases
as the treatment rates increase (Figure 3.6 a-d). The YDA is also increased over time. In the
first year, treatment at stage III has the highest YDA followed by treatment at stage II and
stage I. After 3 years, however, a reverse order is observed, showing that the early treatment
is beneficial in saving lives in a long run (or in the later part of the epidemic). On increasing
treatment rates from 0.20 to 0.40 in any stage, the YDA can be increased by 1.5 fold in the
5th year (Figure 3.6 a, b). Similarly, an increase in treatment from 0.20 to 0.80 results in YDA
twice as large in the 5th year (Figure 3.6 a, d).
We predict 10-year HIV prevalence under the single group treatment program. The preva-
lence can be reduced from 19% to 11%, 17% and 18% by treating individuals at stages I, II and
III, respectively. These results show that treatment programs at stage I and II are less effective
compared to stage I, to reduce the prevalence. We also observe a similar effect on the basic
reproduction number, ℜ0. Treatment at stage I can reduce R0 as much as 66% (from 3.3 to
1.1) while there is negligible effect of treatments at stages II and III on ℜ0. Unfortunately,
single group treatment programs (at τi = 1, i = 1, 2, 3 ) do not reduce ℜ0 below 1 indicating
that the single group treatment program alone at this rate is not enough to eliminate the disease
(Theorem 3.3.1).
Multi-group treatment program
We found that almost 80% of new infections can be reduced by universal treatment (at τi =
1, i = 1, 2, 3 ), i.e. by treating individuals in all stages (Figure 3.4 b), which is almost twice as
much as that achieved from any single group treatment. Only 30% reduction of new infections
can be achieved by treatment at both stages II and III combined. With treatment programs
combining stages I and II, or stages I and III, the total new infections can be reduced by 60%
and 68%, respectively.
With treatment program focused on any two stages combined, the disease death can be
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Figure 3.4: Total new infections in five year period with (a) single group treatment program,
(b) multi-group treatment program.
reduced by almost 50% in 5 years. In this case, the YDA can be achieved up to about 35% at
20% treatment level. When all three stages are included in the treatment program (universal
treatment) the disease death can be reduced by 65% in 5 years (Figure 3.5 b). This reduction is
twice as much as that achieved from any single group treatment program (Figure 3.5 a,b). By
increasing the universal treatment rate to 0.80 the YDA can be achieved up to 85% (Figure 3.7
d).
With universal treatment, HIV prevalence can be reduced from 19% to 11% in 10 years
(Figure 3.8 b). The longterm prevalence under the universal treatment program predicted by
our model shows that at least 50 years are required to reduce the prevalence to below 5%
(Figure 3.8 c), indicating that treatment alone might not be an efficient way for reducing the
current HIV prevalence in a relatively short time period.
We also computed ℜ0 under various treatment combinations. With treatment at stage II
and stage III combined (i.e. τ2 = τ3 = 1), ℜ0 reduces from 3.30 to 2.67. The other treatment
combinations (stage I and stage II or stage II and stage III, or stages I, II, and III) show signif-
icant effective in reduction of ℜ0. All of these remaining treatment combinations can reduce
ℜ0 from 3.30 to 0.85 (Figure 3.9 b). Importantly, the universal treatment program can reduce
ℜ0 to below 1. However, to reduce R0 to below 1, a high treatment rate is required (Figure
3.9 b). The region in treatment-parameter space where ℜ0 < 1 is shown in Figure 3.10. Since
treatment at stage II and stage III combined does not reduce ℜ0 to less than 1, we did not
include this graph.
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Figure 3.5: Total AIDS death in five year period with (a) single group treatment program, (b)
multi-group treatment program.
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Figure 3.6: Yearly death avoidance (YDA) by single group treatment program, (a) treatment
rate 0.20, (b) treatment rate 0.40, (c) treatment rate 0.60, (d) treatment rate 0.80.
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Figure 3.7: Yearly death avoidance (YDA) by multi group treatment program, (a) treatment
rate 0.20, (b) treatment rate 0.40, (c) treatment rate 0.60, (d) treatment rate 0.80.
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Figure 3.8: Model prediction of HIV prevalence under treatment program; (a) prevalence after
10 years with single group treatment program, (b) prevalence after 10 years with multi-group
treatment program, (c) long term projections with universal treatment program.
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Figure 3.9: ℜ0 vs. treatment coverage level, (a) single group treatment program, (b) multi-
group treatment program.
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Figure 3.10: Region where ℜ0 < 1 and ℜ0 > 1 (a) in τ1-τ2 parameter space, (b) in τ1-τ3
parameter space.
3.6 Discussion
Studies show that early ART can be a successful intervention for HIV infection. However, ap-
propriate initiation timing of ART still remains unclear. This study takes the modeling approach
to highlight the population dynamics of HIV infection under treatment programs with various
initiation timing of ART. The model developed here is unique in the sense that it is based on
individual’s CD4+ T cell count, which is important in disease progression, HIV transmission
and treatment decisions.
CD4+ T cells are key components of our immune system and the main target of HIV infec-
tion. The T cell count can reflect the overall strength of the immune system in an individual.
As ART can aid recovery of CD4+ T cells in HIV infected individuals, inclusion of this re-
covery rate in modeling can predict the true effect of ART on the immune levels of treated
individuals. Our model considers this recovery rate and predicts the immune levels of the HIV
infected community with treatment programs. It also estimates the immune levels without
this recovery rate and shows the effect of recovery on the immunity of the treated population
(Figure 3.3). Thus, our model is suitable for evaluating the strength and timing of treatment
programs. Moreover, our model has excellent agreement with HIV prevalence data for a long
period (Figure 3.2).
Using our model, we evaluate the benefits of initiating ART at different CD4+ T cell count
stages. We evaluate the effects of ART programs designed to target a single group or multiple
groups in the population. Using a case study in South Africa, we found that early treatment
(treatment at stage I) can reduce new infections by 2.5 fold more than treatment at stage II
and treatment at stage III. It also shows that early treatment can reduce the total number of
new infections by 25% more than treatment at stage II and stage III combined (Figure 3.4
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a,b). Treatment at stage I also has a greater effect on adult prevalence and ℜ0 as compared to
treatments at stage II and stage III. An early ART program prevents transmission of infections
much earlier while late treatment allows HIV positive individual to spread infections for a
longer period; as a result early treatment works better to reduce ℜ0 and adult prevalence in the
long run. A study of universal testing with immediate ART [23] suggests that prevalence can
be reduced to below 1% in 50 years; consistent with this, our study also finds that universal
treatment at the 50% level can reduce the prevalence to less than 3% in 50 years (Figure 3.8,
c).
In contrast, the timing of initiation of ART does not have a significant effect on the total
disease death (Figure 3.5). However, treatment at stage III is more effective to avoid death at
the beginning of the treatment program, while treatment at stage I is more beneficial in avoiding
death in the long run or later part of the treatment program (Figure 3.6).
The universal treatment program shows a better outcome than single group treatment pro-
grams. In each of the cases of new infections, disease death, prevalence, and ℜ0, a universal
treatment program can provide significantly more benefit than a single group treatment pro-
grams (Figure 3.4).
Treatment has significant effects on HIV transmission and prevalence, but it may not be
able to eliminate the disease unless an extremely high proportion of HIV infected individuals
is brought into the treatment program. Since this high coverage of ART is highly unlikely,
elimination of disease is unlikely by ART alone and alternate interventions (such as condom
promotion, pre-exposure prophylaxis etc.) should be implemented in combination.
Our model (3.1) captures some vital aspects of HIV dynamics and is in excellent agreement
with the data [48]. The model however has several limitations. First, the model does not
distinguish the population by sexes. Second, the model does not address the issues of adherence
to ART and drug resistance. If a patient misses doses of ART and/or resistance arises, our
results may be altered. Third, we did not distinguish individuals with known and unknown
status and assumed that once an individual is HIV positive, he/she is able to start receiving
ART if he/she belongs to the target group. Moreover, we ignore the possible behaviour changes
of individuals after he/she becomes infected.
We explored a mathematical model to estimate the potential benefits of ART at the popula-
tion level and to assess the impact on its time of initiation. Our results based on a South African
population suggest that early ART has the potential to alter the epidemic greatly. The impact of
ART on this South African population can be extrapoated to other countries or regions world
wide. However, these results are subject to change with updates to ART efficacy and newly
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available interventions.
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Chapter 4
Modelling the impact of vaccination on
infectious disease dynamics
4.1 Introduction
Vaccine has a successful history since Edward Jenner’s discovery of smallpox vaccine in the
eighteenth century [17]. His innovation is widely regarded as the foundation of immunology.
With the rapid pace of vaccine development medical science has saved millions of lives from
dreadful diseases during the last two centuries. Small pox eradication can be worth mentioning
as a successful example in this regard [1,29]. Vaccines also contribute significantly to reducing
infections of influenza, polio and many other life threatening diseases [20, 28]. In today’s life
it is unusual and rare for a child not to receive any vaccines.
A vaccine has similar physical properties to those of a pathogen. Similar to pathogens vac-
cines can stimulate the immune system of hosts and builds up antibody against the pathogen.
Thus, whenever such a microorganism is encountered within a host, the immune system de-
stroys it. This kind of phenomenon is known as immunity. Thus, as long as a vaccine for a
disease is available, it is an ideal means of protecting healthy population from the disease.
An individual may receive vaccines available for a disease that is prevalent in his region.
Vaccines of some diseases are already developed and one can take the vaccine if the particular
disease is threaten for him. For example, an individual can take a polio vaccine or a seasonal
flu vaccine which are already available. However, when a new infectious disease emerges but
no vaccine is available for it, the disease may cause significant infections and deaths. It takes
some time to devise an effective vaccine if successful.
Once a vaccine is available, a natural and immediate question arises: how to allocate and
71
Chapter 4. Modelling the impact of vaccination on infectious disease dynamics 72
implement this vaccine [30,33]. Certainly we can not vaccinate all the individuals to eradicate
the disease overnight. In addition to social and ethical issues, high cost may prevent universal
distribution of vaccines [24]. Certain group of individuals may pose higher risk to the infec-
tions than the others. In influenza, for example, school-going children can be infected more
easily and can spread the disease more rapidly than other individuals [9, 15, 19, 20]. Thus to
control infections by using vaccines, a proper distribution and implementation strategy is very
important. Priority may need to be given to certain group(s) or individuals by the health pro-
fessionals. Current practice of vaccine allocation highlights the importance of identifying the
groups which are at highest risk for adverse health [23]. Effectiveness of such a vaccine allo-
cation strategy can be determined through analysis of a mathematical model. In this chapter,
we aim to shed some light on this critical issue and hope to provide a useful guideline to the
policymaker.
To properly implement the vaccination campaign, a plausible and intellectual idea may
be to immunize individuals belonging to certain groups or locations that are most vulnerable
to infections. The transmission rates in these groups are much higher than those in the other
groups in which individuals are less susceptible or they are located in a comparatively safe area.
The individuals in the target groups may need more protections so that the overall infections
can be controlled effectively. In this chapter, we formulate and analyze a mathematical model
that incorporates prioritized group-vaccination strategy.
The rest of this chapter is organized as follows. In Section 4.2, we formulate a two-group
model based on the individual’s risk status. The basic reproduction number of the model, the
equilibria of the model and their stability, as well as the disease persistence are discussed in
Section 4.3. Finally, in Section 4.4, we discuss the policy of vaccine allocation and distribution
based on the model outcomes and offer some concluding remarks.
4.2 Mathematical Model
As indicated in the previous section, we divide the total population into two groups: the risky
(r) group in which the transmission rates are much higher within the group; and the critical (c)
group in which the individuals are conscious in their social behavior, or the individuals that
remain isolated and are less likely to have contact with the infected group, and subsequently
their transmission rate is much lower within the group.
Let the number of population in each group be divided into susceptible (S) and infected (I)
sub-classes. Having infection from either infected sub-class, a susceptible individual becomes
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infected and remains in that sub-class in his/her entire life. The susceptible individuals from
each group are vaccinated at a constant rate and transferred into a common vaccinated (V)
sub-class. We do not consider the vertical infection and assume that susceptibles are recruited
at constant rates. The flow diagram of population is shown in Figure 4.1.
Figure 4.1: Schematic diagram.
As mentioned earlier, we consider two different groups in the population according to their
risk level. The symbols and notations are explained in Table 4.1. The infection mechanism is
considered to be followed by saturating incidence [2, 3, 14] defined by
h(I) = I
1 + αI
, (4.1)
where α ≥ 0 determines the saturation level when the infectious population is large. When
α = 0, this reduces to the mass action incidence rate. The infection rate increases with the
number of infected individuals when this number is small. As the infected number increases
the infection rate becomes plateaued. This phenomenon reflects the saturation of infected
numbers also known as ’crowding effect’. With this assumption the dynamics of the population
is governed by the following equations.

˙S r = Λr −
(
βrr
Ir
1 + αrIr
+ βrc
Ic
1 + αcIc
)
S r − (µ + θr)S r,
˙S c = Λc −
(
βcr
Ir
1 + αrIr
+ βcc
Ic
1 + αcIc
)
S c − (µ + θc)S c,
˙Ir =
(
βrr
Ir
1 + αrIr
+ βrc
Ic
1 + αcIc
)
S r − (µ + νr)Ir,
˙Ic =
(
βcr
Ir
1 + αrIr
+ βcc
Ic
1 + αcIc
)
S c − (µ + νc)Ic,
˙V = θrS r + θcS c − µV.
(4.2)
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Table 4.1: Description of variables and parameters of model (4.3).
Parameter Description
S r number of susceptible in group r
S c number of susceptible in group c
Ir number of infected in group r
IP number of infected in group c
V number of vaccinated individuals
N total number of individuals
β
j
i contact rate of susceptible and infective (i, j = r, c)
νi disease induced death rate (i = r, c)
µ natural death rate
θr vaccination rate to the group r
θc vaccination rate to the group c
We distinguish the groups according to contact rates and our assumption is
βrr ≫ βcr ≥ βrc ≫ βcc.
4.3 Analysis of the model
4.3.1 Well-posedness of the model
The model (4.2) consists of five equations, but the last equation is decoupled. To analyze the
model, it suffices to consider the dynamics of the following system

˙S r = Λr −
(
βrr
Ir
1 + αrIr
+ βrc
Ic
1 + αcIc
)
S r − (µ + θr)S r,
˙S c = Λc −
(
βcr
Ir
1 + αrIr
+ βcc
Ic
1 + αcIc
)
S c − (µ + θc)S c,
˙Ir =
(
βrr
Ir
1 + αrIr
+ βrc
Ic
1 + αcIc
)
S r − (µ + νr)Ir,
˙Ic =
(
βcr
Ir
1 + αrIr
+ βcc
Ic
1 + αcIc
)
S c − (µ + νc)Ic.
(4.3)
For biological reason, we need to investigate the boundedness and positivity of the solutions of
our model. To this end, the first equation can be written as
˙S r = Λr − φ(t)S r,
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where
φ(t) = βrr
Ir
1 + αrIr
+ βrc
Ic
1 + αcIc
+ µ + θr.
It follows that
S r = S r0e−
∫ t
0 φ(s)ds + Λre−
∫ t
0 φ(s)ds
∫ t
0
e
∫ τ
0 φ(s)dsdτ,
which is non-negative as long as S r0 ≥ 0. Similarly, it can be shown that S c ≥ 0. To show that
Ir and Ic are non-negative, consider the sub-system of (4.3)

˙Ir =
(
βrr
Ir
1 + αrIr
+ βrc
Ic
1 + αcIc
)
S r − (µ + νr)Ir,
˙Ic =
(
βcr
Ir
1 + αrIr
+ βcc
Ic
1 + αcIc
)
S c − (µ + νc)Ic.
(4.4)
Since S r and S c are non-negative, this sub-system is cooperative. By monotone property [31]
we conclude that Ir and Ic are non-negative provided that Ir(0) ≥ 0 & Ic(0) ≥ 0.
Now we consider the boundedness of the model. By adding all the equations in (4.3) it can
be shown that the total number of individuals satisfies
lim sup
t→∞
(S r + S c + Ir + Ic) ≤ (Λr + Λc)/(µ + θ),
where θ = min{θr, θc}. Therefore, the biologically feasible region of the model (4.3) is
Ω =
{
(S r, S c, Ir, Ic) : S r, S c, Ir, Ic ≥ 0, S r + S c + Ir + Ic ≤ (Λr + Λc)/(µ + θ)
}
.
4.3.2 Basic reproduction number
The model (4.3) has a disease-free equilibrium (DFE) E0 = (Λr/(µ + θr),Λc/(µ + θc), 0, 0),
but there are no boundary endemic equilibria (i.e. one infected class is present while other is
absent). The stability of E0 is closely related to the notion of the basic reproduction number
for the model, denoted by R0, which plays an important role in determining the disease persis-
tence. The number R0 is defined as “the expected number of secondary cases produced, in a
completely susceptible population, by a typical infected individual” (see, e.g., [7]). This thresh-
old parameter determines whether the disease persists or dies out from the population. We use
next-generation matrix [34] to compute R0. The non-negative matrix F and the non-singular
M-matrix T, known as new-infection and transition matrices respectively, for the system (4.3),
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are given by
F =

βrr
Λr
(µ+θr) β
r
c
Λr
(µ+θr)
βcr
Λc
(µ+θc) β
c
c
Λc
(µ+θc)
 , T =
 µ + νr 00 µ + νc
 .
It follows that
FT−1 =

βrr
Λr
(µ+θr)(µ+νr) β
r
c
Λr
(µ+θr)(µ+νc)
βcr
Λc
(µ+θc)(µ+νr) β
c
c
Λc
(µ+θc)(µ+νc)
 .
The basic reproduction number is then defined by
R0 = ρ
(
FT−1
)
,
where ρ(A) is the spectral radious of A. The explicit formula for R0 is given in Section 4.4. By
Theorem 2 in [34], we obtain the following result on the stability/instability of E0.
Theorem 4.3.1 IfR0 < 1, the DFE E0 is locally asymptotically stable; E0 is unstable ifR0 > 1.
4.3.3 Global stability of E0
In this section, we study the global stability of the DFE E0 for the model (4.3). The local
stability of E0 is already established by Theorem 4.3.1; however we use this theorem to further
obtain the global stability of E0.
The Jacobian matrix of (4.3) at E0 is given by
J (E0) =

−(µ + θr) 0 −βrr Λ
r
(µ+θr) −βrc Λ
r
(µ+θr)
0 −(µ + θc) −βcr Λ
c
(µ+θc) −βcc Λ
c
(µ+θc)
0 0 βrr Λ
r
(µ+θr) − (µ + νr) βrc Λ
r
(µ+θr)
0 0 βcr Λ
c
(µ+θc) β
c
c
Λc
(µ+θc) − (µ + νc)

.
Clearly, −(µ+ θr) and −(µ+ θc) are two eigenvalues of J (E0) which are negative, and the other
two eigenvalues are determined by the lower right block of J (E0), that is,
J22 =

βrr
Λr
(µ+θr) − (µ + νr) βrc Λ
r
(µ+θr)
βcr
Λc
(µ+θc) β
c
c
Λc
(µ+θc) − (µ + νc)
 .
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Hence, the stability of E0 fully depends on the matrix J22.
For any given square matrix A, let s(A) denote the stability modulu of A (i.e., the largest
real part of all eigenvalues of A). Combining the above observation with Theorem 4.3.1, we
immediately have following corollary.
Corollary 4.3.2 If R0 < 1, then s(J22) < 0; if R0 > 1, then s(J22) > 0.
We are now able to prove the following global result.
Theorem 4.3.3 When R0 < 1, E0 is globally asymptotically stable.
Proof: From the ˙S r equation in (4.3), we have ˙S r ≤ Λr − (µ + θr)S r, which implies that
lim sup
t→∞
S r(t) ≤ Λ
r
µ + θr
.
Similarly,
lim sup
t→∞
S c(t) ≤ Λ
c
µ + θc
.
Thus, for any ε > 0, there exists T1 > 0 such that
S r(t) ≤ Λ
r + ε
(µ + θr) , S
c(t) ≤ Λ
c + ε
(µ + θc) for t ≥ T1. (4.5)
Applying the estimates in (4.5) to (4.4), we obtain

˙Ir
˙Ic
 =

(βrr I
r
1+αr Ir + β
r
c
Ic
1+αcIc )S r − (µ + νr)Ir
(βcr I
r
1+αr Ir + β
c
c
Ic
1+αcIc )S c − (µ + νc)Ic

≤

(βrrIr + βrcIc)S r − (µ + νr)Ir
(βcr Ir + βccIc)S c − (µ + νc)Ic

≤

βrr
Λr+ε
(µ+θr) − (µ + νr) βrc Λ
r
(µ+θr)
βcr
Λc+ε
(µ+θc) β
c
c
Λc
(µ+θc) − (µ + νc)

 IrIc
 for t ≥ T1.
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Thus, the sub-system (4.4) has an upper comparison system which is linear and cooperative
with following coefficient matrix
A(ε) =

βrr
Λr+ε
(µ+θr) − (µ + νr) βrc Λ
r+ε
(µ+θr)
βcr
Λc+ε
(µ+θc) β
c
c
Λc+ε
(µ+θc) − (µ + νc)
 .
Obviously, A(ε) depends on ε continuously and A(0) = J22. Since s(J22) < 0, by continuity, we
can choose ε sufficiently small so that s(A(ε)) < 0. Thus, all solutions of this comparing linear
system tend to (0, 0)T as t → ∞. By the standard comparison argument [31], we conclude that
for every non-negative solution of (4.3), its Ir and Ic components also approach to 0 as t → ∞.
The above established limits Ir(t) → 0 and Ic(t) → 0 as t → ∞ indicate that the subsystem
of (4.3) consisting of ˙S r and ˙S c equations has the following limit system:

˙S r = Λr − (µ + θr)S r,
˙S c = Λc − (µ + θc)S c.
(4.6)
Since every solution of (4.6) tends to (Λr/(µ+θr),Λc/(µ+θc))T , by the theory of asymptotically
autonomous systems (see,e.g., Castillo-Chaves and Thieme [6]), the (S r(t), S c(t)) portion of
any non-negative solution of (4.3) also approaches (Λr/(µ + θr),Λc/(µ + θc))T . Therefore,
every non-negative solution of (4.3) converges to the disease free equilibrium E0. The global
attractiveness of E0 and the local stability established in Theorem 4.3.1 lead to the global
asymptotical stability of E0, completing the proof of the theorem.
4.3.4 Persistence of the disease
When R0 > 1, the DFE becomes unstable and it is natural to expect that the infectious pop-
ulations Ir and Ic will remain persistent in this case. In this sub-section, we confirm this
expectation. Indeed, we will prove the following theorem.
Theorem 4.3.4 Assume that R0 > 1. Then the disease is uniformly persistent in the sense that
there exists an η > 0 such that for every positive solution of (4.3), there holds
lim inf
t→∞
Ir(t) > η, lim inf
t→∞
Ic(t) > η.
Moreover, there exists an endemic equilibrium E∗ in this case.
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Proof. We shall apply a theorem in [32] to prove the uniform persistence. To this end, we
set
X =
{
(S r, S c, Ir, Ic) ∈ R4+
}
,
X0 =
{
(S r, S c, Ir, Ic) ∈ X : Ir, Ic > 0
}
,
Y = X/X0 =
{
(S r, S c, Ir, Ic) ∈ X : and Ir = 0 or Ic = 0
}
.
Now we show that the system (4.3) is uniformly persistent with respect to (X0,Y). Since Y
contains only a single equilibrium E0, we need to show that W s(E0) ∩ X0 = φ, where W s(E0)
denotes the stable manifold of E0. Suppose this is not true. Then there is a (S r0, S c0, Ir0, Ic0) ∈ X0
and the corresponding solution of (4.3) with this initial point satisfies
lim
t→∞
(S r(t), S c(t), Ir(t), Ic(t)) → (Λr/(µ + θr),Λc/(µ + θc), 0, 0).
Thus, for any ξ > 0, there is T2 > 0 such that
(Λr − ξ)/(µ + θr) ≤ S r ≤ (Λr + ξ)/(µ + θr),
(Λc − ξ)/(µ + θc) ≤ S c ≤ (Λc + ξ)/(µ + θc),
0 ≤ Ir ≤ ξ, 0 ≤ Ic ≤ ξ,
for t ≥ T2. (4.7)
It follows from (4.3) and (4.7) that

˙Ir
˙Ic
 ≥

βrr
Λr−ξ
µ+θr
1
1+αrξ − (µ + νr) βrc
Λr−ξ
µ+θr
1
1+αcξ
βcr
Λc−ξ
µ+θc
1
1+αrξ β
c
c
Λc−ξ
µ+θc
1
1+αcξ − (µ + νc)


Ir
Ic
 ,
=: ˜J(ξ)

Ir
Ic
 , for t ≥ T2.
This means that the subsystem (4.4) has a lower comparison system which is linear and coop-
Chapter 4. Modelling the impact of vaccination on infectious disease dynamics 80
erative with the coefficient matrix
˜J(ξ) =

βrr
Λr−ξ
µ+θr
1
1+αrξ − (µ + νr) βrc
Λr−ξ
µ+θr
1
1+αcξ
βcr
Λc−ξ
µ+θc
1
1+αrξ β
c
c
Λc−ξ
µ+θc
1
1+αcξ − (µ + νc)
 .
Note that s( ˜J(ξ)) is continuous in ξ and s( ˜J(0)) > 0 (since R0 > 1), we can choose ξ > 0 suf-
ficiently small such that s( ˜J(ξ)) > 0, implying that positive solutions of the lower comparing
system grow exponentially. By the standard comparison argument, Ir(t) or/and Ic(t) compo-
nents of the solution of (4.3) grow unbounded as t → ∞. This is a contradiction to the fact
that the solutions of the system (4.3) are ultimately bounded. Therefore, W s(E0) ∩ X0 = φ.
Now the persistence of the system (4.3) follows from the Theorem 4.6 in [32]. Further more,
by Theorems 3.3 in [13], we know that uniform persistence and the dissipativity established in
previous sub-section implies that system (4.3) has an endemic equilibrium (i.e. all components
are positive) E∗. The proof of the theorem is completed.
The stability of E∗ will be discussed in the next sub-section.
4.3.5 Global stability of E∗
In this sub-section, we investigate the global stability of the endemic equilibrium E∗ under the
condition R0 > 1. To this end, we apply a Lyapunov function similar to those recently used
by [11, 16, 21]. Such Lyapunov functions take advantage of the properties of the function
g(x) = x − 1 − ln(x), (4.8)
which is positive in (0,∞) except at x = 1 where it vanishes. For convenience of notations in
constructing Lyapunov functions, we also make use of the following two functions:
fi(x) = x1 + αix , i = c, r.
Now we establish following result.
Theorem 4.3.5 The endemic equilibrium E∗ = (S r∗, S c∗, Ir∗, Ic∗ ,V∗ is globally attractive when-
ever it exists.
Proof: Consider the Lyapunov function
L = S r∗g
(
S r
S r∗
)
+ S c∗g
(
S c
S c∗
)
+ Ir∗g
(
Ir
Ir∗
)
+ Ic∗g
(
Ic
Ic∗
)
+ V∗g
(
V
V∗
)
.
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Obviously, V is non-negative in the positive cone Ω and attains zero at E∗. We need to show
that ˙L is negative definite. Differentiating V along the trajectories of (4.2), we obtain
˙L =
(
1 − S
r
∗
S r
)
˙S r +
(
1 − S
c
∗
S c
)
˙S c +
(
1 − I
r
∗
Ir
)
˙Ir +
(
1 − I
c
∗
Ic
)
˙Ic +
(
1 − V∗
V
)
˙V
=
(
1 − S
r
∗
S r
) (
Λr − βrr
IrS r
1 + αrIr
− βrc
IcS r
1 + αcIc
− (µ + θr)S r
)
+
(
1 − S
c
∗
S c
) (
Λc − βcr
IrS c
1 + αrIr
+ βcc
IcS c
1 + αcIc
− (µ + θc)S c
)
+
(
1 − I
r
∗
Ir
) (
βrr
IrS r
1 + αrIr
+ βrc
IcS r
1 + αcIc
− (µ + νr)Ir
)
+
(
1 − I
c
∗
Ic
) (
βcr
IrS c
1 + αrIr
+ βcc
IcS c
1 + αcIc
− (µ + νc)Ic
)
+
(
1 − V∗
V
)
(θrS r + θcS c − µV) .
Now using the equilibrium equation at E∗ and simplifying, we have
˙L = βrrS r∗ fr(Ir∗)
[
2 +
fr(Ir)
fr(Ir∗)
− I
r
∗S r fr(Ir)
IrS r∗ fr(Ir∗)
− S
r
∗
S r
− I
r
Ir∗
]
+ βrcS r∗ fc(Ic∗)
[
2 +
fc(Ic)
fc(Ic∗)
− I
r
∗S r fc(Ic)
IrS r∗ fc(Ic∗)
− S
r
∗
S r
− I
r
Ir∗
]
+ βcrS c∗ fr(Ir∗)
[
2 +
fr(Ir)
fr(Ir∗)
− I
c
∗S c fr(Ir)
IcS c∗ fr(Ir∗)
− S
c
∗
S c
− I
c
Ic∗
]
+ βccS c∗ fc(Ic∗)
[
2 +
fc(Ic)
fc(Ic∗)
− I
c
∗S c fc(Ic)
IcS c∗ fc(Ic∗)
− S
c
∗
S c
− I
c
Ic∗
]
+ µS r∗
(
2 − S
r
∗
S r
− S
r
S r∗
)
+ µS c∗
(
2 − S
c
∗
S c
− S
c
S c∗
)
+ θrS r∗
(
3 − S
r
∗
S r
− V
V∗
− S
rV∗
S r∗V
)
+ θcS c∗
(
3 − S
c
∗
S c
− V
V∗
− S
cV∗
S c∗V
)
.
In the above expression the last four terms are obviously non-positive. We only need to show
that the terms in the square brackets are non-positive. Due to similarity we only deal with one
group of square brackets and show that it is non-positive. By using g function defined in (4.8),
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we proceed with the expression of first square bracket of the last equation as
2 +
fr(Ir)
fr(Ir∗)
− I
r
∗S r fr(Ir)
IrS r∗ fr(Ir∗)
− S
r
∗
S r
− I
r
Ir∗
= −g
(
S r
S r∗
)
− ln
(
S r∗
S r
)
− g
(
Ir∗S r fr(Ir)
IrS r∗ fr(Ir∗)
)
− ln
(
Ir∗S r fr(Ir)
IrS r∗ fr(Ir∗)
)
+
fr(Ir)
fr(Ir∗)
− I
r
Ir∗
≤ − ln
(
Ir∗ fr(Ir)
Ir fr(Ir∗)
)
+
fr(Ir)
fr(Ir∗)
− I
r
Ir∗
= − ln
(
1 + αrIr∗
1 + αrIr
)
+
Ir
Ir∗
(
1 + αrIr∗
1 + αrIr
)
− I
r
Ir∗
.
Now we show that the above quantity is non-positive. Let
H(x) = −ln
(
1 + ax0
1 + ax
)
+
x
x0
1 + ax0
1 + ax
− x
x0
.
Taking the derivative, we have
H′(x) = 1(1 + ax)2x0
[
ax0(1 + ax) + 1 + ax0 − (1 + ax)2
]
.
Note that H′(x) only has a positive zero x0. It is easy to see that H(x) attains the maximum
H(x0) = 0 only at x0. Consequently, ˙L ≤ 0 with equality holding only at the equilibrium E∗.
By [12], all positive solutions approach M, the largest invariant subset of the set { dLdt = 0} .
Since dLdt is zero only at E∗, M = {E∗} is a singleton set. Thus, the equilibrium E∗ is globally
attractive.
4.4 Discussion
In this chapter we aim to investigate the vaccine implementation policy of an infectious dis-
ease in a resource constrained environment. Transmission of a disease largely depends on the
nature of infected individuals, locations, modes of transmission, infection-causing organisms.
Certain group(s) of people may have high risk of receiving and transmitting infections whereas
other individuals exhibit less susceptibility and infectivity. Therefore, the infection of disease
significantly depends on individual’s risk level. Considering this fact, we have proposed a sim-
ple two-group model incorporating vaccination rates. In our analysis, the model demonstrate
a global threshold dynamics in terms of the combined parameter R0 — the secondary infec-
tion rate referred to as the basic reproduction number, as described in Theorem 4.3.1, Theorem
4.3.3, Theorem 4.3.4 and Theorem 4.3.5. More precisely, if R0 < 1, then the disease will be
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eliminated over time; and R0 > 1 the disease will remain endemic and infectious populations
will approach to positive constant levels.
Obviously, from the viewpoint of controlling the disease, one would naturally like to reduce
the basic reproduction number. Thus, it is worthwhile to investigate how we can reduce R0
effectively by a proper implementation of vaccines. Calculating the spectral radius of the next
generation matrix FV−1 gives the following explicit formula for R0:
R0 =
1
2
[
βrrΛ
r
(µ + θr)(µ + νr) +
βccΛ
c
(µ + θc)(µ + νc)
+
√(
βrrΛ
r
(µ + θr)(µ + νr) −
βccΛ
c
(µ + θc)(µ + νc)
)2
+
4βrcβcrΛrΛc
(µ + θr)(µ + νr)(µ + θc)(µ + νc)

=
1
2
[
βrrGrr + βccGcc +
√(
βrrGrr − βccGcc
)2
+ 4βrcβcrGrcGcr
]
,
where
Grr =
Λr
(µ + θr)(µ + νr) , G
r
c =
Λc
(µ + θr)(µ + νc) ,
Gcr =
Λr
(µ + θc)(µ + νr) , G
c
c =
Λc
(µ + θc)(µ + νc) .
Based on the above formula, we have following observations on R0.
Observation I: The two groups are weakly connected
In this case, the contact matrix is nearly reducible, that is, at least one of the cross contact rates
βrc or β
c
r is near 0. Then, the threshold parameter R0 has the following approximation:
R0 ≈ 12
[
βrrGrr + βccGcc + |
(
βrrGrr − βccGcc
) |] = max {βrrGrr, βccGcc} .
Due to higher contact rate of risky group, we may assume that βrrGrr > βccGcc. Then we have
R0 ≈ βrrGrr =
βrrΛ
r
(µ + θr)(µ + νr) .
That is, R0 does not depend on vaccination of critical group anymore. Moreover, R0 is decreas-
ing with θr (the vaccination rate of risky group). The vaccination rate has positive effect on the
reduction of disease. The condition βrrGrr > βccGcc will hold in a region where the disease is
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highly infectious (just like Ebola outbreak in West African countries [8, 18]). In this situation,
when question arises on vaccine implementation, “vaccine to risky group only” strategy would
be better policy. This policy seems to be more crucial when vaccines are economically costly
and insufficient, and more doses are required to provide full-immunity. Providing enough doses
to the risky individuals rather than single shot to randomly chosen individuals from both groups
should be more effective to control disease.
Now we consider the case βrrGrr < βccGcc which may occur when the recruitment to risky
group is significantly smaller than that in the critical group. This scenario prevails in a re-
gion where comparatively greater portion of the population are less susceptive (small βcc) and
incoming susceptibles with lower susceptibility are also considerably larger (big Λc ) in the
respective group. By symmetry, the basic reproduction number becomes
R0 ≈ βccGcc =
βccΛ
c
(µ + θc)(µ + νc) .
It is surprising that vaccine to the risky individuals do not bring any benefit to reduce R0.
Because of weak connections ( βrc ≈ 0 or βcr ≈ 0) between the groups, the risky group could not
deteriorate the disease situation in the whole population. However, the susceptible individuals
in risky group are more vulnerable to infection. So, if vaccines are available they also need
to be immunized to protect them even though this vaccination may not have a major effect on
global disease control.
Observation II: Both groups are strongly connected
Now we investigate the scenario when both groups are strongly connected (i.e. contacts matrix
is irreducible). Assume that both cross-contact rates βrc and βcr are positive. We need to look
into the threshold parameter R0 more deeply. Observe that R0 depends on four compound pa-
rameters βrrGrr, βrcGrc, βcrGcr and βccGcc. So we need to determine the key parameter among the
following four components
βrrGrr =
βrrΛ
r
(µ + θr)(µ + νr) , β
r
cGrc =
βrcΛ
r
(µ + θr)(µ + νc) ,
βcrGcr =
βcrΛ
c
(µ + θc)(µ + νr) , β
c
cGcc =
βccΛ
c
(µ + θc)(µ + νc) ,
that contribute more to increase R0 in the absence of vaccination. Notice that the quantities
differ significantly on β ji G
j
i (i, j = r, c). By the nature of grouping, it is assumed βri ≫ βci (i =
r, c) so that βriΛr > βciΛc (i = r, c). Therefore, increasing θr (vaccination rate in risky group)
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would be more effective than uniform vaccination policy.
In this work, we divide the host into two groups for implementing vaccines effectively.
However, in reality there may be no clearly well-defined line between the groups. Moreover,
there may be more than two groups, differed by contact rates or risk factors etc. The immuniza-
tion campaign may be administered by giving priorities to the groups having higher risk factor.
The population may be grouped in different ways, but we would emphasize the importance of
some grouping before initiating vaccine campaign.
Our model or the group-strategic method can be applied to implement vaccines or control
measures in various infectious diseases, for example, influenza, measles or ebola. In fact,
the grouping strategy can be found in the current practice of vaccine distributions [5, 20] and
proven to be effective against a possible outbreak [33]. In influenza, school-going children are
considered to be the most target group followed by elderly individuals [9, 25]. Vaccinating
healthy children against influenza has the potential to reduce the epidemic [9, 15, 19, 20]. It
is found that by vaccinating 70% school-going children the over-all influenza infection can
be reduced to below the epidemic level [20]. The children posses less pre-immunity while
encounter highest exposures- become easy target for transmission disease. The age-specific
population with increased risk, pregnant women, individuals with critically illness and health
workers could be other potential target groups. The group-strategic method can also be applied
to HIV or STDs (sexually transmitted diseases). However, an appropriate model is required
for STDs as our model (4.2) is, in general, not suitable to the STDs. STD can be spread more
rapidly in some particular groups such as sexual workers, men-sex-with-men (MSM) group,
injection-drug users (IDUs) and so on [4, 10]. These core groups should be given highest
priority for allocating and implementing vaccines.
Another grouping of the host can be made through regional basis. A disease may outbreak
in a certain region with facile transmissibility and high case fatality where as individuals in
the other regions are comparatively safe due to geographical distance. The recent outbreak
of Evola virus, for example, in West Africa threats with striking case fatality (50-90%) and
transmissibility [8, 18, 22, 26]. The individuals surrounding the region are highly risky than
those are in the outer world. In this scenario, the individuals in that region should be vaccinated
with utmost priority. Next preference may be given to the health workers of outer region. Since
they are among the first line of exposures. As reported, some nurses in USA got infected while
caring of Ebola infected patients [27].
While this study offers some guideline on vaccine implementations, our model has some
limitations. We do not consider the behavior change or the movement between the two groups.
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For simplicity, the model do not distinguish the infected population according to their disease
progression (certain disease like HIV progress over the time) and uses a single transmission rate
from all infected individuals. In our model (4.3), we do not distinguish the mode of transmis-
sion and population are not divided into sexes. In case of sexually transmitted disease (STD),
an individual can be infected through sexual contact or by sharing needles; other diseases, like
flu or dengue, can be spread through airborne or vector-borne transmissions. We also ignore
vertical transmission (mother to new born) and passive immunity to keep the model simple.
Finally, our goal is to find out an optimal vaccination strategy, not to demonstrate a rigorous
analysis of a mathematical model. The formulation of the model (4.3) may underestimate or
overestimate the real R0. However, this estimate does not influence the consequences of the
outcome of our analysis. That is, the proper estimation ofR0 does not violate the grouping idea;
rather it helps group management. The model can be improved by incorporating several real-
istic aspects. For example, to assert on immunization we may further investigate into the delay
and waning of vaccine immunity, lack of vaccine efficacy and impact of vaccine complicacy.
We leave these as possible future research projects.
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Chapter 5
Conclusions and future directions
In this thesis, we studied transmission and prevention mechanisms of some infectious diseases
through mathematical models. Persistence of current infections and their possible dynamics
under existing and new interventions are investigated. We also addressed global stability of
some epidemic models.
In Chapter 1, we reviewed some basic features of infectious diseases, their orientation, his-
torical background, and intervention efforts. This chapter also highlights the role of modelling
and its challenges.
In Chapter 2, we considered an HIV model to project the effectiveness of tenofovir gel
against HIV transmission and prevalence on the adult population of South Africa. This par-
ticular pre-exposure prophylaxis gel was experimented in a small scale near the Durban city
of South Africa and showed 39%-54% effectiveness against women infection. Our model pre-
dicts that the tenofovir gel can reduce the population level transmission by up to 72% along
with existing interventions. This study demonstrates that coverage and retention of gel are key
factors that determine the optimum benefits from the gel and suggested that resistance can also
affect the outcomes.
In Chapter 3, we developed an HIV model to demonstrate the consequences of antiretroviral
treatment on the new infections, community immunity level, and long term prevalence. The
model is based on CD4+ T cell counts that signify individual’s immunity level. This study
addressed the impact of various ART programs on the HIV epidemic and demonstrated the
effect of ART on the community immunity levels. The study also demonstrated that early
treatment is significantly effective as compared to delayed treatment program on HIV epidemic.
Our results found that ART alone is unlikely to eliminate HIV, but it can significantly contribute
to reduce the overall HIV transmission and prevalence, and to alter the current trend of HIV
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dynamics.
In Chapter 4, we investigated the aspect of hierarchies of susceptible population in terms
of their risk of susceptibility and how these hierarchies can determine the distribution policy
of vaccines and others intervention tools. A mathematical model was developed to investi-
gate the optimum strategy of vaccine distribution. This study suggest that susceptible popu-
lations should be divided into groups by risk status to secure optimum benefit from a vaccine
campaign. Our results support the ongoing vaccine distribution strategy and its results for
influenza.
We addressed certain aspects of the underlying problems and ignored several other aspects
of those problems to keep the models simple. As further studies and future directions, one
may include additional realistic features in our models. Some additional aspects include age-
structure, latency delay, spatial heterogeneity and networking. These are all important aspects
for some diseases and should be considered when modelling these diseases’ dynamics.
In many infectious diseases such as Ebola, measures of control change continuously based
on surveillance, intensity of infection, resource availability, and invention of new tools. One
may investigate time dependency on transmission rate and other parameters of a model under
a continuous changes of control measures. Drug resistance is a critical issue in HIV infection.
By including drug resistance in HIV models (Chapters 2 & 3), we may improve modelling
outcomes significantly .
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